Bioelectrode composition, bioelectrode, and method for producing bioelectrode
By using a combination of ionic polymer materials, hydrogen silicon-based polysilicon oxygen and platinum group catalysts, the problems of changes in conductivity and skin allergies in biological electrodes during long-term use are solved, and low-cost manufacturing and high-sensitivity organisms are achieved Body electrodes to ensure that the electrodes do not leave any residue on the skin.
Patent Information
- Application Number
- CN202111299558.0
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Priority Date
- 2020-11-05
- Filing Date
- 2021-11-04
- Publication Date
- 2024-12-03
- Estimated Expiration
- 2041-11-04
AI Technical Summary
Existing biological electrodes are prone to changes in conductivity, skin allergies and residue problems during long-term use, and are difficult to manufacture at low cost and at low cost, and are difficult to maintain conductivity and biocompatibility.
The biological electrode composition containing ionic polymer materials, hydrogen silicon-based addition reaction hardened polysilicon oxygen and platinum group catalysts is used to form conductivity and biological suitability through specific solvent selection and treatment methods. Excellent biological contact layer ensures that the electrodes do not leave residue on the skin.
It realizes biological electrodes with excellent conductivity and biological fitness, can be manufactured at low cost, and will not cause skin allergies or residues for a long time, and maintain high sensitivity electrical signal acquisition capabilities.
Smart Images

Figure CN114431864B_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to a biological electrode that contacts the skin of a living body and can detect body conditions such as heart rate by using electrical signals from the skin, a method for manufacturing the same, and a biological electrode composition suitable for the biological electrode. Background Art
[0002] In recent years, with the popularization of IoT (Internet of Things), the development of wearable devices has also progressed. Clocks and glasses that can be connected to the Internet are representative examples. In addition, in the medical field and sports field, there is also a need for wearable devices that can monitor the body's condition at any time, which is a field with future growth potential.
[0003] In the medical field, for example, some people are studying wearable devices that monitor the status of body organs by sensing weak currents, such as electrocardiogram measurement, which uses electrical signals to sense heartbeats. Electrodes coated with conductive paste are installed on the body and measured, but this is a short-term measurement that is only performed once. In contrast, the development of medical wearable devices such as the above-mentioned ones aims to develop devices that monitor health status at any time for several consecutive days. Therefore, for biological electrodes used in medical wearable devices, it is required that there will be no changes in conductivity and no skin allergies even when used for a long time. In addition, they are also required to be lightweight and able to be manufactured at a low cost.
[0004] As the novel coronavirus spreads around the world, the need for home medical care has been emphasized to prevent the collapse of medical care due to the large number of virus-infected patients being hospitalized beyond hospital capacity. Some people have proposed online medical treatment in which doctors in hospitals can diagnose the health status of people at home, and they are seeking to develop low-cost and high-precision wearable devices.
[0005] There are two types of medical wearable devices: those that are attached to the body and those that are incorporated into clothing. As for the type that is attached to the body, a biological electrode using a water-soluble gel containing water and electrolytes as the material of the above-mentioned conductive paste has been proposed (Patent Document 1). Regarding the water-soluble gel, sodium, potassium, and calcium are contained as electrolytes in a water-soluble polymer for retaining water, and changes in ion concentration from the skin are converted into electricity. On the other hand, as a type that is incorporated into clothing, a method has been proposed in which a cloth having a conductive polymer such as PEDOT-PSS (Poly-3,4-ethylenedioxythiophene-Polystyrenesulfonate) and a silver paste incorporated into the fiber is used as an electrode (Patent Document 2).
[0006] However, when using the above-mentioned water-soluble gel containing water and electrolytes, there is a problem that the conductivity will also disappear when the water disappears due to drying. On the other hand, when using metals with a high tendency to dissociate such as copper, there is a risk of causing skin allergies in some people. When using conductive polymers such as PEDOT-PSS, there is also a risk of causing skin allergies due to the strong acidity of the excess polystyrene sulfonic acid that is not used in the doping of the conductive polymer, and there is a problem that the conductive polymer peels off from the fiber during washing.
[0007] In addition, metal nanowires, carbon black, and carbon nanotubes have excellent electrical conductivity, so some people have explored using them as electrode materials (Patent Documents 3, 4, 5). Since the probability of metal nanowires contacting each other increases, a small amount of addition can conduct electricity. However, metal nanowires are fine materials with pointed tips, so they can cause skin allergies. For the same reason, carbon nanotubes are also irritating to organisms. Although carbon black is not as toxic as carbon nanotubes, it is still somewhat irritating to the skin. As mentioned above, even if the substance itself does not cause an allergic reaction, it may sometimes deteriorate in biocompatibility due to the shape and irritation of the material, and it is difficult to have both conductivity and biocompatibility.
[0008] It is believed that the conductivity of metal films is very high, so they will function as excellent biological electrodes, but this is not necessarily the case. The current released from the skin due to the beating of the heart is not just weak, but also sodium ions, potassium ions, and calcium ions. Therefore, the concentration change of ions must be converted into current, but precious metals that are not easily freed are not efficient in converting ions from the skin into current. Therefore, the impedance of biological electrodes using precious metals is high, and the current passing through the skin is high resistance.
[0009] Some people have proposed bioelectrodes with ionic polymers added (Patent Documents 6, 7, 8). Bioelectrodes obtained by adding mixed ionic polymers and carbon powder to a silicone adhesive have high adhesiveness and water repellency, so they can stably collect biosignals even if they are attached to the skin for a long time while showering or sweating. In addition, ionic polymers do not pass through the skin, so they are non-irritating to the skin and have high biocompatibility, so they are also bioelectrodes that can be installed for a long time.
[0010] Polysilicon is an insulator, but by combining it with an ionic polymer and carbon powder, its ionic conductivity improves and it can function as a biological electrode. However, further improvement of ionic conductivity is still needed to enhance performance.
[0011] Printable electronic devices that use printing to manufacture devices are gaining attention. If biological devices can also be produced by roll-to-roll printing, productivity will be improved and costs will be reduced. Printable electronic devices are also characterized by being light and thin. In order to reduce the sense of installation when attached to the skin, they also need to be light, thin and short.
[0012] Wearable devices must not leave residue on the skin even after being attached to the skin for several days and then peeled off. In particular, biological electrodes must not only have sufficient adhesion to attach to the skin, but also have sufficient membrane strength to prevent residue after peeling off.
[0013] In order to produce bioelectrodes by printing, there must be a time margin from the preparation of the ink for printing the bioelectrode to printing, or from printing to baking to solidify the film. If there is no such time margin, for example, if there is no time margin from the preparation of the ink to printing, the time must be strictly controlled, and it will be impossible to cope with the situation where the printing device stops due to sudden problems. In order to enable stable production by printing, materials that can ensure a time margin from the preparation of the ink to printing and until the film is hardened are required.
[0014] Prior art literature
[0015] Patent Literature
[0016] [Patent Document 1] International Publication No. 2013 / 039151
[0017] [Patent Document 2] Japanese Patent Application Publication No. 2015-100673
[0018] [Patent Document 3] Japanese Patent Application Laid-Open No. 5-095924
[0019] [Patent Document 4] Japanese Patent Application Publication No. 2003-225217
[0020] [Patent Document 5] Japanese Patent Application Publication No. 2015-019806
[0021] [Patent Document 6] Japanese Patent Application Publication No. 2018-99504
[0022] [Patent Document 7] Japanese Patent Application Publication No. 2018-126496
[0023] [Patent Document 8] Japanese Patent Application Publication No. 2018-130533 Summary of the invention
[0024] Problems to be solved by the invention
[0025] In order to solve the above-mentioned problems, the present invention aims to provide a biological electrode composition that can form a biological contact layer for a biological electrode that has excellent conductivity and biocompatibility, is lightweight and can be manufactured at low cost, is attached to the skin and does not leave any residue on the skin after being peeled off, a biological electrode with a biological contact layer formed by the biological electrode composition, and a manufacturing method thereof.
[0026] How to solve the problem
[0027] In order to achieve the above-mentioned problems, the present invention proposes the following bioelectrode composition and bioelectrode.
[0028] That is, the present invention provides a biological electrode composition, comprising (A) an ionic polymer material, (B) an addition reaction-hardening polysiloxane having at least a hydrosilyl group, (C) a platinum-group catalyst, and a solvent, wherein the water content in the biological electrode composition is less than 0.2% by mass, and the solvent comprises one or more of an ether-based, ester-based, and ketone-based solvent that does not contain a hydroxyl group, a carboxyl group, a nitrogen atom, or a thiol group.
[0029] The bioelectrode composition of the present invention can form a biocontact layer for a bioelectrode that has excellent conductivity and biocompatibility, is lightweight and can be manufactured at low cost, and does not leave residue on the skin after being attached to the skin and peeled off.
[0030] The aforementioned biological electrode composition is a mixture of a solution containing the aforementioned ionic polymer material as component (A), the aforementioned addition reaction-curable polysiloxane having at least a hydrogen silicon group as component (B), and a solution containing the aforementioned platinum group catalyst as component (C), and the water content in the aforementioned component (A) and the aforementioned component (B) may be less than 0.2% by mass.
[0031] If it is such a biological electrode composition, since the water content of (A) component and (B) component is low, the deactivation reaction of the hydrogen silicon group will not occur when (A) component and (B) component are just mixed. Even if (A) component, (B) component and (C) component are mixed and placed to form a biological electrode, it will not leave residue on the skin after being attached to the skin to obtain biological signals and then peeled off.
[0032] In this case, the solvent of the solution of the aforementioned component (A) may be any one or more of ether, ester and ketone solvents that do not contain a hydroxyl group, a carboxyl group, a nitrogen atom or a thiol group, and the aforementioned component (B) may be a solution without a solvent, or a solution of a hydrocarbon or ether solvent.
[0033] The ionic polymer material of component (A) is easily soluble in any one or more of the ether, ester and ketone solvents due to its high polarity, and the organopolysiloxane having a hydrosilyl group of component (B) is easily soluble in a hydrocarbon or ether solvent (or no solvent is required). When mixing components (A) and (B), if the ionic polymer compound (polymer material) is dissolved in the solvent in advance, the mixing can be carried out quickly.
[0034] Furthermore, in the biological electrode composition of the present invention, the aforementioned ionic polymer material in the aforementioned component (A) is preferably a polymer compound containing repeating units having a structure selected from the sodium salt, potassium salt, or silver salt of any one of fluorosulfonic acid, fluorosulfonyl imide, and N-carbonylfluorosulfonamide.
[0035] Such a bioelectrode composition is suitable for forming a biocontact layer for a bioelectrode that has excellent conductivity and biocompatibility, is lightweight, can be manufactured at low cost, and does not significantly reduce conductivity even when wetted by water or dried.
[0036] In this case, the aforementioned structure is preferably represented by the following general formulas (1)-1 to (1)-4.
[0037] [Chemistry 1]
[0038]
[0039] In the formula, Rf1 and Rf2 are hydrogen atoms, fluorine atoms, oxygen atoms, methyl groups, or trifluoromethyl groups. When Rf1 is an oxygen atom, Rf2 is also an oxygen atom and forms a carbonyl group together with the bonded carbon atom. Rf3 and Rf4 are hydrogen atoms, fluorine atoms, or trifluoromethyl groups, and one or more of Rf1 to Rf4 are fluorine atoms or trifluoromethyl groups. Rf5, Rf6, and Rf7 are fluorine atoms, linear alkyl groups having 1 to 4 carbon atoms, or branched alkyl groups having 3 or 4 carbon atoms, and have at least one fluorine atom. m is an integer of 1 to 4. M is sodium, potassium, or silver.
[0040] Such a biological electrode composition can achieve better effects of the present invention.
[0041] Furthermore, it is preferred that the repeating units have one or more repeating units selected from the sodium salt, potassium salt, silver salt of fluorosulfonic acid represented by the aforementioned general formula (1)-1 or (1)-2, the sodium salt, potassium salt, silver salt of sulfonimide represented by (1)-3, or the sodium salt, potassium salt, silver salt of sulfonamide represented by (1)-4, and it is preferred that the repeating units have one or more repeating units selected from the repeating units a1 to a7 described in the following general formula (2).
[0042] [Chemistry 2]
[0043]
[0044] In the formula, R1 , R 3 , R 5 , R 8 , R 10 , R 11 , and R 13 are each independently a hydrogen atom or a methyl group, R 2 , R 4 , R 6 , R 9 , and R 12 are each independently a single bond, an ester group, or a linear, branched, or cyclic divalent hydrocarbon group having 1 to 13 carbon atoms that may also have either an ether group or an ester group, or may have both. R 7 is a linear alkylene group having 1 to 4 carbon atoms or a branched alkylene group having 3 to 12 carbon atoms, and one or two of the hydrogen atoms in R 7 may be replaced by a fluorine atom. X1, X2, X3, X4, and X6 are each independently a single bond, a phenylene group, a naphthylene group, an ether group, an ester group, or an amide group, X5 is a single bond, an ether group, or an ester group, X7 is a single bond, an arylene group having 6 to 12 carbon atoms, or -C(=O)-O-X 10 -, X 10 is a linear, branched, or cyclic alkylene group having 1 to 12 carbon atoms or a divalent aromatic hydrocarbon group having 6 to 10 carbon atoms, and X 10 may also have an ether group, a carbonyl group, or an ester group. Y is an oxygen atom or a -NR 19 - group, R 19 is a hydrogen atom, a linear alkyl group having 1 to 4 carbon atoms, or a branched alkyl group having 3 or 4 carbon atoms, and Y and R 4 may also be bonded to form a ring. m is an integer from 1 to 4. a1, a2, a3, a4, a5, a6, and a7 satisfy 0 ≤ a1 ≤ 1.0, 0 ≤ a2 ≤ 1.0, 0 ≤ a3 ≤ 1.0, 0 ≤ a4 ≤ 1.0, 0 ≤ a5 ≤ 1.0, 0 ≤ a6 ≤ 1.0, 0 ≤ a7 ≤ 1.0, and 0 < a1 + a2 + a3 + a4 + a5 + a6 + a7 ≤ 1.0. M, Rf5, Rf6, Rf7 are as described above.
[0045] If it is such a biological electrode composition, the effects of the present invention can be made better.
[0046] Further, in the present invention, the component (B) may contain an organopolysiloxane having a hydrosilyl group.
[0047] Further, the component (B) may, in addition to containing an organopolysiloxane having a hydrosilyl group, further contain a diorganopolysiloxane having an alkenyl group.
[0048] The biological electrode composition of the present invention is suitably used with such a component (B).
[0049] In addition, the component (B) may further contain a compound having R x SiO (4-x) / 2 Unit (R is a substituted or unsubstituted monovalent hydrocarbon group having 1 to 10 carbon atoms, and x is in the range of 2.5 to 3.5) and a polysilicone resin having a SiO2 unit.
[0050] When such a component (B) is contained, the adhesive strength is improved.
[0051] Furthermore, in the present invention, the component (A) may contain a diorganosiloxane having an alkenyl group in addition to the ionic polymer material.
[0052] The bioelectrode composition of the present invention preferably uses such component (A).
[0053] In addition, the component (A) may further contain a compound having R x SiO (4-x) / 2 Unit (R is a substituted or unsubstituted monovalent hydrocarbon group having 1 to 10 carbon atoms, and x is in the range of 2.5 to 3.5) and a polysilicone resin having a SiO2 unit.
[0054] When such a component (A) is contained, the adhesive strength is improved.
[0055] In the present invention, the component (A) or the component (B) may further contain one or more selected from carbon powder, metal powder, silicon powder, lithium titanate powder and metal chloride powder as the component (D).
[0056] By further adding such conductive powder (carbon powder, metal powder, silicon powder, lithium titanate powder, and metal chloride powder), the conductivity can be further improved.
[0057] In this case, the carbon powder is preferably any one of carbon black, graphite and carbon nanotubes or a combination thereof, and may further contain ionic components.
[0058] If this is done, the conductivity can be made better.
[0059] Furthermore, the metal powder is preferably a metal powder selected from gold, silver, platinum, copper, tin, titanium, nickel, aluminum, tungsten, molybdenum, ruthenium, chromium, and indium, and silver powder is particularly preferred.
[0060] If this is done, the electronic conductivity can be improved.
[0061] Furthermore, the present invention provides a method for producing a biological electrode composition, which is the method for producing the above-mentioned biological electrode composition, characterized in that the aforementioned (A) ionic polymer material, the aforementioned (B) addition reaction-hardening polysiloxane having at least a hydrogen silicon group, and the aforementioned (C) platinum group catalyst are stored in separate containers and mixed to form the biological electrode composition when producing the biological electrode.
[0062] The method for manufacturing a biological electrode composition of the present invention can efficiently and inexpensively manufacture a biological electrode composition that can form a biological contact layer for a biological electrode that has excellent conductivity and biocompatibility, is lightweight, adheres to the skin, and does not leave residue on the skin after being peeled off.
[0063] In the method for producing the bioelectrode composition of the present invention, the component (D) may be mixed with the component (A) or the component (B) before or simultaneously with the component (C).
[0064] According to such a method for producing a bioelectrode composition, the influence of water from the component (D) can be reduced.
[0065] Furthermore, the present invention provides a bioelectrode comprising a conductive substrate and a biocontact layer formed on the conductive substrate, wherein the biocontact layer is a hardened product of the bioelectrode composition.
[0066] The biological electrode of the present invention has excellent conductivity and biocompatibility, is lightweight, and does not leave residue on the skin after being attached to the skin and peeled off.
[0067] In this case, the conductive substrate preferably contains one or more selected from the group consisting of gold, silver, silver chloride, platinum, aluminum, magnesium, tin, tungsten, iron, copper, nickel, stainless steel, chromium, titanium, carbon, and a conductive polymer.
[0068] The present invention is suitably used with such a conductive substrate.
[0069] Furthermore, the present invention provides a method for manufacturing a biological electrode, which is a method for manufacturing a biological electrode having a conductive substrate and a biological contact layer formed on the conductive substrate, characterized in that the above-mentioned biological electrode composition is coated on the above-mentioned conductive substrate and hardened to form the above-mentioned biological contact layer.
[0070] According to the method for producing a biological electrode of the present invention, a biological electrode which has excellent conductivity and biocompatibility, is lightweight, and does not leave residue on the skin after being attached to the skin and peeled off can be produced efficiently and at low cost.
[0071] In this case, it is preferred that the conductive substrate contain one or more selected from the group consisting of gold, silver, silver chloride, platinum, aluminum, magnesium, tin, tungsten, iron, copper, nickel, stainless steel, chromium, titanium, carbon, and a conductive polymer.
[0072] The present invention is suitably used with such a conductive substrate.
[0073] Effects of the Invention
[0074] As described above, the bioelectrode composition of the present invention contains (A) an ionic polymer material, (B) an addition reaction-curable polysiloxane having at least a hydrosilyl group, (C) a platinum-based catalyst, and a solvent, and is characterized in that the water content in the aforementioned bioelectrode composition is 0.2% by mass or less, and the aforementioned solvent contains at least one of an ether-based, ester-based, and ketone-based solvent that does not contain a hydroxyl group, a carboxyl group, a nitrogen atom, or a thiol group. If it is such a bioelectrode composition, the addition reaction during mixing, coating, and baking of the components (A) to (C) is not hindered, and the film can be cured, and the film strength is sufficient. When the bioelectrode is attached to the skin to measure the biosignal and is peeled off, no residue is generated on the skin. Even if the time from mixing (A) to (C) to printing is long, and the time from printing to baking is long, the sufficient film strength can be maintained, and no residue is generated after peeling. If the components (A) to (C) are placed in separate containers, they will not deteriorate due to long-term storage.
[0075] Furthermore, the biological electrode of the present invention has sufficient adhesiveness and a constant contact area with the skin, and can stably obtain electrical signals from the skin with high sensitivity.
[0076] Furthermore, the method for manufacturing the biological electrode of the present invention can easily manufacture the biological electrode of the present invention by low-cost printing, which has excellent conductivity and biocompatibility, is lightweight, and does not significantly reduce conductivity even when wetted by water or dried.
[0077]
Simple explanation of the diagram
[0078] Figure 1 A schematic cross-sectional view showing an example of the biological electrode of the present invention.
[0079] Figure 2 A schematic cross-sectional view showing an example of a biological electrode according to the present invention being installed in a living body.
[0080] Figure 3 A schematic diagram showing a printed biological electrode produced according to an embodiment of the present invention.
[0081] Figure 4 A schematic diagram showing a state in which one of the biological electrodes produced in an example of the present invention is cut out and attached to an adhesive layer.
[0082] Figure 5 A diagram showing the locations where electrodes and ground are attached to the human body when measuring biological signals in an embodiment of the present invention.
[0083] Figure 6 An electrocardiogram waveform obtained using the biological electrode according to the embodiment of the present invention is shown. DETAILED DESCRIPTION
[0084] As described above, we seek to develop a biological electrode composition that can form a biological contact layer for a biological electrode that has excellent conductivity and biocompatibility, is lightweight and can be manufactured at low cost, can be attached to the skin and does not leave any residue on the skin after being peeled off, a biological electrode that forms a biological contact layer using the biological electrode composition, and a method for manufacturing the same.
[0085] When weak current and sodium, potassium, and calcium ions are released from the skin surface in conjunction with the heartbeat, the bioelectrode needs to convert the increase or decrease of these ions released from the skin into an electrical signal. Therefore, the bioelectrode needs to be made of a material with excellent ion conductivity to transmit the increase or decrease of ions.
[0086] The inventors of the present application have focused on ionic liquids for materials with high ionic conductivity. Ionic liquids have high thermal stability and chemical stability, and have excellent electrical conductivity. Their application in battery applications is expanding. In addition, ionic liquids are known to include hydrochlorides, hydrogen bromides, hydrogen iodides, trifluoromethanesulfonates, nonafluorobutanesulfonates, bis(trifluoromethanesulfonyl)imide salts, hexafluorophosphates, tetrafluoroborate, etc. of sulfonium, phosphonium, ammonium, morpholinium, pyridinium, pyrrolidinium, and imidazolium. However, in general, these salts (especially those with small molecular weight) have high hydration properties, so the bioelectrode obtained by forming a biocontact layer with a bioelectrode composition to which these salts are added has the disadvantage of reduced conductivity due to salt extraction caused by sweat and washing. In addition, tetrafluoroborate has high toxicity and other salts have high water solubility, so it is easy to penetrate into the skin, which may cause skin roughness (i.e., strong irritation to the skin).
[0087] If the acidity of the acid forming the neutralized salt is high, the ions will be strongly polarized and the ionic conductivity will increase. For lithium-ion batteries, the lithium salts of bis(trifluoromethanesulfonyl)imidic acid and tris(trifluoromethanesulfonyl)methyl acid show high ionic conductivity for this reason. On the other hand, the higher the acid strength, the stronger the biological irritation of the salt. In other words, there is a trade-off between ionic conductivity and biological irritation. However, salts used in biological electrodes must take into account both high ionic conductivity and low biological irritation.
[0088] The larger the molecular weight of the salt compound and the higher the steric structure, the lower the permeability to the skin and the lower the irritation to the skin. Therefore, the inventors of the present application conceived of adding an ionic polymer compound to the biological electrode composition.
[0089] In addition, the inventors of the present application have thought that by using this salt mixed with an adhesive (resin), it is possible to keep the adhesive in close contact with the skin and obtain a stable electrical signal for a long time. With respect to the adhesive, considering the biocompatibility, skin respiration, and the viewpoint of suppressing the deformation of the skin during peeling and suppressing redness, it is believed that the use of a silicone adhesive is better.
[0090] The silicone adhesive is a mixture of cross-linked silicone and MQ resin. For the cross-linking reaction, free radical cross-linking using the decomposition of peroxide or hydrosilylation reaction of hydrosilyl and vinyl is used. For the biological electrode composition, adding carbon is effective for improving the conductivity, but carbon absorbs free radicals, so carbon cannot be added when cross-linking reaction using free radicals is used. On the other hand, hydrosilylation reaction is not hindered by carbon.
[0091] Hydrosilyl groups react with water and compounds with active protons such as hydroxyl, carboxyl, and thiol groups. For example, if a hydrosilyl group reacts with water, it will become a silanol group, and the hydrosilylation reaction with the vinyl group will not proceed. Therefore, in order to make the hydrosilylation reaction proceed, the water content must be low, and compounds with active protons such as hydroxyl, carboxyl, and thiol groups should not be added to the solvent.
[0092] What is likely to contain water is not the polysiloxane with hydrogen silyl groups of component (B), but the solution of the ionic polymer compound (polymer material) containing component (A). When the water contained in the solution (A) is mixed with the solution (B), the above-mentioned deactivation reaction of the hydrogen silyl groups will occur. Therefore, the solution of the ionic polymer compound containing component (A) needs to be dehydrated. The dehydration treatment can be carried out by azeotropic dehydration to increase the concentration of the solution containing the ionic polymer compound, or by using a dehydrating agent such as a molecular sieve.
[0093] The inventors of the present application have made intensive researches on the above-mentioned problems and have found that if the water content in the bioelectrode composition is low and the content of compounds having active protons such as hydroxyl, carboxyl, and thiol groups can also be suppressed to a small amount, the deactivation reaction of the hydrosilyl groups when mixed with them will be suppressed without hindering the hydrosilylation reaction. In this way, a bioelectrode formed by a bioelectrode composition having limited water content and content of compounds having active protons can be attached to the skin and no residue will be generated on the skin after peeling off, thus completing the present invention.
[0094] That is, the present invention is a biological electrode composition comprising (A) an ionic polymer material, (B) an addition reaction-hardening polysiloxane having at least a hydrosilyl group, (C) a platinum-group catalyst, and a solvent, wherein the water content in the biological electrode composition is less than 0.2% by mass, and the solvent comprises one or more of an ether-based, ester-based, and ketone-based solvent that does not contain a hydroxyl group, a carboxyl group, a nitrogen atom, or a thiol group.
[0095] The present invention will be described in detail below, but the present invention is not limited to these.
[0096] In addition, each of the following components includes a solution containing the component.
[0097] <Biological Electrode Composition>
[0098] The bioelectrode composition of the present invention comprises (A) an ionic polymer material, (B) an addition reaction-curable polysiloxane having at least a hydrosilyl group, (C) a platinum-based catalyst, and a solvent, wherein the water content in the bioelectrode composition is 0.2% by mass or less, and the solvent comprises one or more of an ether-based, ester-based, and ketone-based solvent that does not contain a hydroxyl group, a carboxyl group, a nitrogen atom, or a thiol group. As described later, components other than the above components (A) to (C) may be contained as necessary.
[0099] If the water content in the bioelectrode composition is high, the hydrosilyl groups of the polysiloxane in the composition react with water to form silanol groups, and crosslinking by the reaction of Si-H groups with hydrosilyl groups such as Si-vinyl groups in the presence of a platinum-based catalyst does not proceed. If the crosslinking reaction does not proceed, the membrane strength becomes weak, and when the bioelectrode is attached and peeled off, the membrane is damaged, and bioelectrode residues appear on the skin.
[0100] In particular, in the case of a biological electrode composition formed by mixing a solution containing (A) an ionic polymer material, (B) an addition reaction-curable polysilicone, and a solution containing (C) a platinum-group catalyst, if the water content of each of the solution of the aforementioned component (A) and the solution of the aforementioned component (B) exceeds 0.2% by mass, the hydrogensilyl groups of the polysilicone in the mixed component (B) will react with water to become silanol groups, and the above tendency will become significant.
[0101] In addition, for the solution containing the (A) ionic polymer material, when it contains hydroxyl groups, carboxyl groups, nitrogen atoms, and thiol groups, it will also cause the solvent to react with the hydrosilyl groups, and the proportion of the hydrosilyl groups will decrease, resulting in the hindrance of the hydrosilylation reaction. Ionic polymer materials are easily soluble in solvents containing hydroxyl groups, carboxyl groups, nitrogen atoms, and thiol groups due to their high polarity, but they need to be soluble in ether-based, ester-based, and ketone-based solvents that do not contain hydroxyl groups, carboxyl groups, nitrogen atoms, and thiol groups.
[0102] Therefore, in the bioelectrode composition of the present invention, the water content in the composition is 0.2% by mass or less, and the solvent must contain at least one of ether, ester and ketone solvents that do not contain hydroxyl groups, carboxyl groups, nitrogen atoms and thiol groups. In addition, the water content in the solvent, solution and bioelectrode composition can be measured by Karl Fischer method.
[0103] The following is a detailed description of the biological electrode composition of the present invention.
[0104] [(A) ingredient]
[0105] (A) Component is an ionic polymer material. Polysilicone is originally an insulator, but by combining it with an ionic polymer (ionic polymer material), its ionic conductivity is improved and it acts as a biological electrode. There are no special restrictions on the ionic polymer material as long as it has ionic conductivity.
[0106] The ionic polymer material is preferably a polymer compound containing a repeating unit having a structure selected from the group consisting of a sodium salt, a potassium salt, and a silver salt of fluorosulfonic acid, fluorosulfonyl imide, and N-carbonyl fluorosulfonamide.
[0107] If the bioelectrode composition contains such an ionic polymer compound, it is suitable for forming a biocontact layer for a bioelectrode that has excellent conductivity and biocompatibility, is lightweight and can be manufactured at low cost, and whose conductivity does not drop significantly even when wetted by water or dried.
[0108] Furthermore, the ionic repeating unit having the above structure is more preferably represented by any one of the following general formulae (1)-1 to (1)-4.
[0109] [Chemistry 3]
[0110]
[0111] In the formula, Rf1 and Rf2 are hydrogen atoms, fluorine atoms, oxygen atoms, methyl groups, or trifluoromethyl groups. When Rf1 is an oxygen atom, Rf2 is also an oxygen atom and forms a carbonyl group together with the bonded carbon atom. Rf3 and Rf4 are hydrogen atoms, fluorine atoms, or trifluoromethyl groups, and one or more of Rf1 to Rf4 are fluorine atoms or trifluoromethyl groups. Rf5, Rf6, and Rf7 are fluorine atoms, linear alkyl groups having 1 to 4 carbon atoms, or branched alkyl groups having 3 or 4 carbon atoms, and have at least one fluorine atom. m is an integer of 1 to 4. M is sodium, potassium, or silver.
[0112] Furthermore, the ionic repeating unit is more preferably selected from a1 to a7 in the following general formula (2).
[0113] [Chemistry 4]
[0114]
[0115] In the formula, R 1 , R 3 , R 5 , R 8 , R 10 , R 11 , and R 13 are each independently a hydrogen atom or a methyl group, and R 2 , R 4 , R 6 , R 9 , and R 12 are each independently a single bond, an ester group, or a linear, branched, or cyclic divalent hydrocarbon group having 1 to 13 carbon atoms, 3 to 12 carbon atoms, or both an ether group and an ester group. R 7 is a linear alkylene group having 1 to 4 carbon atoms or a branched alkylene group having 3 to 12 carbon atoms, and one or two of the hydrogen atoms in R 7 may be substituted with a fluorine atom. X1, X2, X3, X4, and X6 are each independently a single bond, a phenylene group, a naphthylene group, an ether group, an ester group, or an amide group, X5 is a single bond, an ether group, or an ester group, X7 is a single bond, an arylene group having 6 to 12 carbon atoms, or -C(=O)-O-X 10 -, and X 10 is a linear, branched, or cyclic alkylene group having 1 to 12 carbon atoms or a divalent aromatic hydrocarbon group having 6 to 10 carbon atoms, and X 10 may also have an ether group, a carbonyl group, or an ester group. Y is an oxygen atom or an -NR 19 - group, and R 19 is a hydrogen atom, a linear alkyl group having 1 to 4 carbon atoms, or a branched alkyl group having 3 or 4 carbon atoms. Y and R 4 may also be bonded to form a ring. m is an integer from 1 to 4. a1, a2, a3, a4, a5, a6, and a7 are numbers that satisfy 0 ≤ a1 ≤ 1.0, 0 ≤ a2 ≤ 1.0, 0 ≤ a3 ≤ 1.0, 0 ≤ a4 ≤ 1.0, 0 ≤ a5 ≤ 1.0, 0 ≤ a6 ≤ 1.0, 0 ≤ a7 ≤ 1.0, and 0 < a1 + a2 + a3 + a4 + a5 + a6 + a7 ≤ 1.0. M, Rf5, Rf6, and Rf7 are as described above.
[0116] To obtain a monomer having an ionic repeating unit of a1 to a7 selected from the above general formula (2), specifically, as described in paragraphs
[0061] to
[0091] of Japanese Unexamined Patent Application Publication No. 2020-002342, for the monomers to be copolymerized with it, the copolymerization ratio, the polymerization method, the molecular weight, etc., those described in paragraphs
[0112] to
[0135] can be used.
[0117] When an ionic polymer compound is mixed with an organopolysiloxane having a hydrosilyl group, the mixing will proceed quickly if the ionic polymer compound is dissolved in a solvent in advance. The solvent for dissolving the ionic polymer compound preferably contains less than 0.2% by mass of water and is preferably an ether, ester or ketone solvent having no active protons such as hydroxyl, carboxyl or thiol groups.
[0118] Examples of the ether solvent used to dissolve the ionic polymer compound include ethylene glycol dimethyl ether, ethylene glycol diethyl ether, ethylene glycol dipropyl ether, ethylene glycol methyl butyl ether, ethylene glycol dibutyl ether, propylene glycol dimethyl ether, propylene glycol diethyl ether, propylene glycol dipropyl ether, propylene glycol dibutyl ether, propylene glycol methyl propyl ether, propylene glycol methyl butyl ether, diethylene glycol dimethyl ether, diethylene glycol methyl ethyl ether, diethylene glycol diethyl ether, diethylene glycol divinyl ether, diethylene glycol diallyl ether, diethylene glycol dipropyl ether, diethylene glycol isopropyl methyl ether, diethylene glycol dibutyl ether, diethylene glycol methyl butyl ether, diethylene glycol methyl phenyl ether, diethylene glycol methyl benzyl ether, and diethylene glycol bis(2-propynyl) ether. Ketone solvents include cyclopentanone, 2-carbonylethoxycyclopentanone, 2-methoxycarbonylcyclopentanone, 2-ethoxycarbonylcyclopentanone, 2-heptylcyclopentanone, 2,2,4-trimethylcyclopentanone, 2-cyclopentylcyclopentanone, 2-acetylcyclopentanone, 2-cyclopenten-1-one, 3-methyl-2-cyclopentenone, 2-pentyl-2-cyclopenten-1-one, 2-pentyl-3-methyl-2-cyclopenten-1-one, cyclohexanone, 3,3,5-trimethylcyclohexanone, 4,4-dimethylcyclohexanone, 2-methoxycyclohexanone, 2-propylcyclohexanone, 4-propylcyclohexanone, 3,4-dimethylcyclohexanone, 3,3-dimethylcyclohexanone, 2-cyclohexylcyclohexanone, 2-allylcyclohexanone, 2-methylcyclohexanone, 3-methylcyclohexanone, 4-methylcyclohexanone, 4- Uncle Butylcyclohexanone, 2-acetylcyclohexanone, 4,4'-dimethylcyclohexanone, 3,5-dimethylcyclohexanone, 4-ethylcyclohexanone, 2-sec-butylcyclohexanone, 2-cyclohexen-1-one, 3-methyl-2-cyclohexen-1-one, 4,4-dimethyl-2-cyclohexen-1-one, 3,5,5-trimethyl-2-cyclohexen-1-one, cycloheptanone, 2-octanone, 2-nonanone, 2-heptanone, 3-heptanone, 4-heptanone, 2-hexanone, 3-hexanone, diisobutyl ketone, methylcyclopentanone, methyl n-amyl ketone, acetophenone, methyl acetophenone, propiophenone, isobutyl ketone.
[0119] The ester solvents include propylene glycol monomethyl ether acetate, propylene glycol monoethyl ether acetate, propylene glycol monopropyl ether acetate, propylene glycol monobutyl ether acetate, diethylene glycol monomethyl ether acetate, diethylene glycol monoethyl ether acetate, diethylene glycol monopropyl ether acetate, diethylene glycol monobutyl ether acetate, diethylene glycol diacetate, diethylene glycol monoethyl ether acrylate, diethylene glycol monomethyl ether methacrylate, diethylene glycol diacrylate, diethylene glycol dimethacrylate, ethyl pyruvate, butyl acetate, amyl acetate, hexyl acetate, heptyl acetate, isobutyl acetate, amyl acetate, butyl acetate, isoamyl acetate, ethyl acetate phenyl formate, propyl formate, butyl formate, isobutyl formate, amyl formate, isopentyl formate, methyl valerate, methyl pentenoate, methyl crotonate, ethyl crotonate, methyl 3-methoxypropionate, ethyl 3-ethoxypropionate, tert-butyl acetate, tert-butyl propionate, propylene glycol mono-tert-butyl ether acetate, methyl benzoate, ethyl benzoate, phenyl acetate, benzyl acetate, methyl phenylacetate, benzyl formate, phenylethyl formate, methyl 3-phenylpropionate, benzyl propionate, ethyl phenylacetate, 2-phenylethyl acetate, α-methyl-γ-butyrolactone, α-angelica lactone lactone), δ-valerolactone, γ-valerolactone, β-methyl γ-valerolactone, α-methylene-γ-butyrolactone, γ-methylene-γ-butyrolactone, γ-caprolactone, ε-caprolactone, γ-enantholactone, γ-octanolactone, whiskey lactone, γ-nonalactone, δ-nonalactone, etc.
[0120] [(B) ingredient]
[0121] The component (B) is an addition reaction curing type polysiloxane having at least a hydrosilyl group, and is not particularly limited as long as it has a hydrosilyl group and can be cured by an addition reaction.
[0122] The component (B) may serve as a matrix resin, or may be compatible with the component (A) to prevent the salt from eluting, and may hold the conductivity enhancer and the like when present to develop adhesion.
[0123] The component (B) may contain an organopolysiloxane having a hydrosilyl group, a diorganopolysiloxane having an alkenyl group in addition to the organopolysiloxane having a hydrosilyl group, or a diorganopolysiloxane having an R x SiO (4-x) / 2 A polysilicone resin containing units (R is a substituted or unsubstituted monovalent hydrocarbon group having 1 to 10 carbon atoms, and x is in the range of 2.5 to 3.5) and SiO2 units.
[0124] For example, Japanese Patent Application Laid-Open No. 2015-193803 discloses a diorganosiloxane having an alkenyl group and having R3SiO 0.5 And MQ resins with SiO2 units, and organohydrogenpolysiloxanes with multiple SiH groups (hydrogen silicon groups).
[0125] The biological electrode composition of the present invention is prepared by mixing a solution (A) containing an ionic polymer material and a polysiloxane (B) containing a hydrosilyl group. It is preferred that there are a plurality of hydrosilyl groups in the polysiloxane molecule.
[0126] In order to develop adhesiveness, a compound containing R may be added to either or both of the components (A) and (B). x SiO (4-x) / 2 The polysiloxane resin containing a unit (R is a substituted or unsubstituted monovalent hydrocarbon group having 1 to 10 carbon atoms, and x is in the range of 2.5 to 3.5) and a SiO2 unit is preferably a diorganosiloxane containing an alkenyl group as described in Japanese Unexamined Patent Publication No. 2015-193803, a diorganosiloxane containing an alkenyl group as described in Japanese Unexamined Patent Publication No. 2015-193803, a diorganosiloxane containing an R3SiO 0.5 It is better to mix MQ resin with SiO2 units.
[0127] In addition, the polysiloxane / resin one-piece compound formed by condensation reaction of polysiloxane and MQ resin with silanol in polymer end and side chain can also be used.MQ resin has many silanols, so by adding MQ resin, adhesion can be improved, but without crosslinking, so it will not be molecularly bonded with polysiloxane.As mentioned above, by polysiloxane and resin becoming one-piece, adhesion can be increased.By containing multiple alkenyl groups in the above-mentioned polysiloxane, adhesion can be further increased by crosslinking reaction with hydrogen silicon group.
[0128] [Solvent]
[0129] The biological electrode composition of the present invention contains a solvent. The solvent may be contained according to each component, and these solvents may be the same or different. By dissolving or dispersing each component by a solvent, workability can be improved. On the other hand, depending on the solvent, water may be contained from the beginning or due to hygroscopicity, and if used, the water content in the biological electrode composition will increase. In this way, the hydrogen silyl group of the polysiloxane in the composition reacts with water and becomes a silanol group, and the crosslinking caused by the reaction of the Si-H group with the hydrogen silyl group of the Si-vinyl in the presence of a platinum group catalyst becomes inoperative. If the crosslinking reaction does not proceed, the membrane strength is weakened, and when the biological electrode is attached and peeled off, it will cause damage inside the membrane, and residues of the biological electrode will appear on the skin.
[0130] Furthermore, ionic polymer materials are easily soluble in solvents containing hydroxyl groups, carboxyl groups, nitrogen atoms, and thiol groups due to their high polarity. However, if such solvents are used, active hydrogen in the solvent reacts with hydrosilyl groups, reducing the proportion of hydrosilyl groups and hindering the hydrosilylation reaction.
[0131] In view of the improvement of workability and the suppression of deactivation of hydrosilyl groups, the present invention comprises one or more of ether, ester and ketone solvents that do not contain hydroxyl groups, carboxyl groups, nitrogen atoms and thiol groups. The solvent used in the present invention may contain other solvents as long as it contains such a specific solvent.
[0132] The biological electrode composition of the present invention can be used as long as the water content in the final composition as a whole is less than 0.2 mass%. If such a composition is formed, the water content of the solvent used may also exceed 0.2 mass%. However, considering the viewpoint of suppressing the deactivation of the hydrosilyl group caused by water, it is preferred that the water content in the components (A) and (B) is less than 0.2 mass%, and it is more preferred that the water content in the components other than the component (C) is less than 0.2 mass%. In addition, the platinum group catalyst (C) has a very small blending ratio to the whole, and even if it contains water, the water content in the final composition as a whole can be said to be less than 0.2 mass%. Therefore, the water in the component (C) will not be particularly problematic. The lower the water content, the better, for example, it can be set in the range of 0.0001 to 0.2 mass%.
[0133] The dehydration treatment of the solvent can be carried out according to a conventional method, for example, by azeotropic dehydration or by using a dehydrating agent such as molecular sieves. The dehydration treatment can be carried out in advance or during the process of preparing the composition.
[0134] In addition, a hydrocarbon organic solvent or an ether organic solvent may be added as the component (B) to the biological electrode composition of the present invention. Specific examples of the hydrocarbon organic solvent include toluene, xylene, isopropylbenzene, 1,2,3-trimethylbenzene, 1,2,4-trimethylbenzene, 1,3,5-trimethylbenzene, styrene, α-methylstyrene, butylbenzene, sec-butylbenzene, isobutylbenzene, isopropyltoluene, diethylbenzene, 2-ethyl-p-xylene, 2-propyltoluene, 3-propyltoluene, 4-propyltoluene, 1,2,3,5-tetramethyltoluene, 1,2,4,5-tetramethyltoluene, tetralin, 4-phenyl-1-butene, tert-amylbenzene, pentylbenzene, 2-tert-butyltoluene, 3-tert-butyltoluene, 4-tert-butyltoluene, 5-isopropyl-m-xylene, 3-methylethylbenzene, tert-butyl-3-ethylbenzene, 4-tert-butyl Aromatic hydrocarbon solvents such as 1,2-diisopropylbenzene, 1,3-diisopropylbenzene, 1,4-diisopropylbenzene, dipropylbenzene, pentamethylbenzene, hexamethylbenzene, hexylbenzene, 1,3,5-triethylbenzene, etc.; n-heptane, isoheptane, 3-methylhexane, 2,3-dimethylpentane, 3-ethylpentane, 1,6-heptadiene, 5-methyl-1-hexyne, norbornane, norbornene, dicyclopentadiene, 1-methyl-1,4-cyclohexadiene, 1-heptyne, 2-heptyne, cycloheptane, cycloheptene, 1,3-dimethylcyclopentane, ethylcyclopentane, methylcyclohexane, 1-methyl-1-cyclohexene, 3-methyl-1-cyclohexene cyclohexene, methylene cyclohexane, 4-methyl-1-cyclohexene, 2-methyl-1-hexene, 2-methyl-2-hexene, 1-heptene, 2-heptene, 3-heptene, n-octane, 2,2-dimethylhexane, 2,3-dimethylhexane, 2,4-dimethylhexane, 2,5-dimethylhexane, 3,3-dimethylhexane, 3,4-dimethylhexane, 3-ethyl-2-methylpentane, 3-ethyl-3-methylpentane, 2-methylheptane, 3-methylheptane, 4-methylheptane, 2,2,3-trimethylpentane, 2,2,4-trimethylpentane, cyclooctane, cyclooctene, 1,2-dimethylcyclohexane, 1,3-dimethylcyclohexane, 1,4-dimethylcyclohexane, ethylcyclohexane Hexane, vinyl cyclohexane, isopropyl cyclopentane, 2,2-dimethyl-3-hexene, 2,4-dimethyl-1-hexene, 2,5-dimethyl-1-hexene, 2,5-dimethyl-2-hexene, 3,3-dimethyl-1-hexene, 3,4-dimethyl-1-hexene, 4,4-dimethyl-1-hexene, 2-ethyl-1-hexene, 2-methyl-1-heptene, 1-octene, 2-octene, 3-octene, 4-octene, 1,7-octadiene, 1-octyne, 2-octyne, 3-octyne, 4-octyne, n-nonane, 2,3-dimethylheptane, 2,4-dimethylheptane, 2,5-dimethylheptane, 3,3-dimethylheptane, 3,4-dimethylheptane, 3,5-Dimethylheptane, 4-ethylheptane, 2-methyloctane, 3-methyloctane, 4-methyloctane, 2,2,4,4-tetramethylpentane, 2,2,4-trimethylhexane, 2,2,5-trimethylhexane, 2,2-dimethyl-3-heptene, 2,3-dimethyl-3-heptene, 2,4-dimethyl-1-heptene, 2,6-dimethyl-1-heptene, 2,6-dimethyl-3-heptene, 3,5-dimethyl-3-heptene, 2,4,4-trimethyl-1-hexene, 3,5,5-trimethyl-1-hexene, 1-ethyl-2-methylpentane cyclohexane, 1-ethyl-3-methylcyclohexane, 1-ethyl-4-methylcyclohexane, propylcyclohexane, isopropylcyclohexane, 1,1,3-trimethylcyclohexane, 1,1,4-trimethylcyclohexane, 1,2,3-trimethylcyclohexane, 1,2,4-trimethylcyclohexane, 1,3,5-trimethylcyclohexane, allylcyclohexane, octahydroindene, 1,8-nonadiene, 1-nonyne, 2-nonyne, 3-nonyne, 4-nonyne, 1-nonene, 2-nonene, 3-nonene, 4-nonene, n-decane, 3,3-dimethyloctane, 3,5-dimethyloctane cyclohexane, 4,4-dimethyloctane, 3-ethyl-3-methylheptane, 2-methylnonane, 3-methylnonane, 4-methylnonane, tert-butylcyclohexane, butylcyclohexane, isobutylcyclohexane, 4-isopropyl-1-methylcyclohexane, pentylcyclopentane, 1,1,3,5-tetramethylcyclohexane, cyclododecane, 1-decene, 2-decene, 3-decene, 4-decene, 5-decene, 1,9-decadiene, decahydronaphthalene, 1-decyne, 2-decyne, 3-decyne, 4-decyne, 5-decyne, 1,5,9-decatriene, 2,6-dimethyl-2,4,6 -octatriene, limonene, myrcene, 1,2,3,4,5-pentamethylcyclopentadiene, α-phellandrene, pinene, terpinene, tetrahydrodicyclopentadiene, 5,6-dihydrodicyclopentadiene, dicyclopentadiene, 1,4-decadiyne, 1,5-decadiyne, 1,9-decadiyne, 2,8-decadiyne, 4,6-decadiyne, n-undecane, pentylcyclohexane, 1-undecene, 1,10-undecadiene, 1-undecyne, 3-undecyne, 5-undecyne, tricyclo[6.2.1.0, 2,7 ] undec-4-ene, n-dodecane, 2-methylundecane, 3-methylundecane, 4-methylundecane, 5-methylundecane, 2,2,4,6,6-pentamethylheptane, 1,3-dimethyladamantane, 1-ethyladamantane, 1,5,9-cyclododecatriene, 1,2,4-trivinylcyclohexane, isoparaffins and other aliphatic hydrocarbon solvents. Isoparaffin solvents include ISOPAR C, ISOPAR E, ISOPAR G, ISOPAR H, ISOPAR L, ISOPAR M and ISOPAR V (produced by Standard Petroleum).
[0135] Specific examples of ether-based organic solvents include diisopropyl ether, diisobutyl ether, diisoamyl ether, di-n-amyl ether, methylcyclopentyl ether, methylcyclohexyl ether, di-n-butyl ether, di-sec-butyl ether, di-sec-amyl ether, di-tert-amyl ether, di-n-hexyl ether, anisole, 3-methoxytoluene, 4-methoxytoluene, trans-anethole, etc. In order to suppress the deactivation of the hydrosilyl group, the above-mentioned organic solvents may not have a hydroxyl group, a carboxyl group, a nitrogen atom, or a thiol group.
[0136] The amount of the solvent added is preferably in the range of 10 to 50,000 parts by mass based on 100 parts by mass of the resin of the component (A) or the component (B).
[0137] [(C) ingredient]
[0138] The diorganosiloxane having an alkenyl group and the organohydrogenpolysiloxane having a plurality of hydrosilyl groups can be crosslinked by an addition reaction using a platinum-based catalyst as the component (C).
[0139] The platinum group catalyst of component (C) includes: platinum group catalysts such as chloroplatinic acid, alcohol solutions of chloroplatinic acid, reaction products of chloroplatinic acid and alcohols, reaction products of chloroplatinic acid and olefin compounds, reaction products of chloroplatinic acid and vinyl-containing siloxanes, platinum-olefin complexes, platinum-vinyl-containing siloxane complexes, rhodium complexes, ruthenium complexes, and the like, and platinum group metal catalysts such as the like. In addition, those obtained by dissolving or dispersing these catalysts in alcoholic, hydrocarbon, or siloxane solvents can also be used.
[0140] The amount of the platinum-based catalyst added may be an effective amount, and is preferably in the range of 5 to 2,000 ppm, particularly preferably 10 to 500 ppm, based on 100 parts by mass of the resin.
[0141] By adding the above-mentioned diorganosiloxane having alkenyl groups and R3SiO 0.5 The compatibility with the above-mentioned salts is improved by adding a modified siloxane having a group selected from amino, oxirane, oxetane, polyether, hydroxyl, carboxyl, mercapto, methacrylate, acrylic, phenol, silanol, carboxylic anhydride, aromatic, aromatic alkyl, amide, ester and lactone ring.
[0142] As described later, the living body contact layer is a cured product of the living body electrode composition. By curing the living body contact layer, the adhesion of the living body contact layer to both the skin and the conductive substrate becomes good.
[0143] When an addition-curing silicone resin is used, an addition reaction control agent may be added to component (A) or component (B). The addition reaction control agent is added as a quencher to prevent the platinum-based catalyst from acting in a solution or in a low-temperature environment before heat curing after film formation. Specific examples thereof include 3-methyl-1-butyn-3-ol, 3-methyl-1-pentyn-3-ol, 3,5-dimethyl-1-hexyn-3-ol, 1-ethynylcyclohexanol, 3-methyl-3-trimethylsilyloxy-1-butyn, 3-methyl-3-trimethylsilyloxy-1-pentyn, 3,5-dimethyl-3-trimethylsilyloxy-1-hexyn, 1-ethynyl-1-trimethylsilyloxycyclohexane, bis(2,2-dimethyl-3-butynyloxy)dimethylsilane, 1,3,5,7-tetramethyl-1,3,5,7-tetravinylcyclotetrasiloxane, and 1,1,3,3-tetramethyl-1,3-divinyldisiloxane.
[0144] The amount of the addition reaction control agent added is not particularly limited, but is preferably in the range of 0 to 10 parts by mass, particularly 0.05 to 3 parts by mass, based on 100 parts by mass of the resin.
[0145] [(D) ingredient]
[0146] The biological electrode composition of the present invention may further contain conductive powder as component (D). There are no particular restrictions on the conductive powder as long as it is a powder with conductivity. It is ideal to be selected from one or more of carbon powder (carbon material), metal powder, silicon powder, lithium titanate powder, and metal chloride powder, and carbon powder and / or metal powder is more ideal. It is preferred that component (D) is pre-mixed with component (A) or component (B). By adding such conductive powder (carbon powder, metal powder, etc.), the conductivity can be made better. In addition, hereinafter, conductive powder is also referred to as "conductivity enhancer".
[0147] [Toner]
[0148] Carbon material (carbon powder) may also be added as a conductivity enhancer. Examples of carbon materials include carbon black, graphite, carbon nanotubes, carbon fibers, and the like. Carbon nanotubes may be single-layer or multi-layer, and the surface may be modified by organic groups. Carbon powder may further contain ionic components, that is, the surface or interior of the carbon material (carbon powder) may adsorb or contain ions. By allowing the carbon material to adsorb or contain ions, the ionic conductivity will be further improved and the sensitivity of biological signals will be further improved. Methods for allowing carbon powder to adsorb or contain ions include a method of dispersing the carbon powder in a solution containing ions and then heating while stirring, and a method of injecting ions into the carbon powder. The amount of carbon material added is preferably in the range of 1 to 50 parts by mass relative to 100 parts by mass of the resin.
[0149] [Metal powder]
[0150] In order to improve the electronic conductivity, it is preferred to add a metal powder selected from gold, silver, platinum, copper, tin, titanium, nickel, aluminum, tungsten, molybdenum, ruthenium, chromium, and indium as component (D) to the biological electrode composition of the present invention. The amount of the metal powder added is not particularly limited, but is preferably in the range of 1 to 50 parts by mass relative to 100 parts by mass of the resin.
[0151] Regarding the types of metal powder, gold, silver, and platinum are ideal from the perspective of conductivity, and silver, copper, tin, titanium, nickel, aluminum, tungsten, molybdenum, ruthenium, and chromium are preferred from the perspective of price. From the perspective of biocompatibility, precious metals are ideal, and considering all these factors, silver is the most ideal.
[0152] The shape of the metal powder can be spherical, disc-shaped, flake-shaped, or needle-shaped, but adding flake-shaped powder has the highest conductivity and is more ideal. The size of the metal powder is not particularly limited, but is less than 100 μm and has a tap density of 5 g / cm 3 Below, specific surface area 0.5m 2 Chips with a lower density and a larger specific surface area are preferred. Metal powder and carbon material (carbon powder) can also be added as conductivity enhancers.
[0153] [Silica powder]
[0154] In order to improve the ion reception sensitivity of the biological electrode composition of the present invention, silicon powder can also be added as component (D). Silicon powder can include powders of silicon, silicon monoxide, and silicon carbide. The particle size of the powder is not particularly limited, and it is ideal to be less than 100μm, and more preferably less than 1μm. The finer particles have a large surface area and can receive many ions, becoming a highly sensitive biological electrode. The amount of silicon powder added is not particularly limited, and it is preferably in the range of 1 to 50 parts by mass relative to 100 parts by mass of the resin.
[0155] [Lithium titanate powder]
[0156] In the biological electrode composition of the present invention, lithium titanate powder may be added as component (D) in order to improve the ion receiving sensitivity. Examples of lithium titanate powder include Li2TiO3, LiTiO2, and spinel-structured Li4Ti5O 12 The molecular formula of the present invention is spinel structure, and spinel structure is preferred. In addition, lithium titanate particles composited with carbon can also be used. The particle size of the powder is not particularly limited, and it is ideal to be less than 100μm, and more preferably less than 1μm. The surface area of smaller particles is large, and they can accept many ions, becoming highly sensitive biological electrodes. They can also be composite powders with carbon. The amount of lithium titanate powder added is not particularly limited, and the range of 1 to 50 parts by mass relative to 100 parts by mass of the resin is preferred.
[0157] [Metal chloride powder]
[0158] In the biological electrode composition of the present invention, metal chloride powder can be added as component (D) to improve ionic conductivity. Examples of metal chloride powder include powders of alkali metal chlorides such as sodium chloride and potassium chloride, and alkaline earth metal chlorides such as calcium chloride and magnesium chloride, which are ionic additives described later. Among them, sodium chloride and potassium chloride are preferred. The particle size of the powder is not particularly limited, and it is ideal to be less than 100 μm, and more preferably less than 1 μm. The surface area of finer particles is large, so they can act as ion carriers more efficiently, becoming highly sensitive biological electrodes. They can also be composite powders with carbon (carbon powder further containing ionic components from metal chlorides). In order to make it contain carbon powder, the above-mentioned method of making carbon powder contain ionic components can be used. For example: add carbon powders such as graphite and carbon black to an aqueous solution of metal chlorides such as sodium chloride and potassium chloride or an alcohol dispersion such as methanol, and evaporate the solvent (water, methanol, etc.) while heating and stirring as needed to obtain ion-treated carbon powder. The amount of the metal chloride powder added is not particularly limited, but is preferably in the range of 1 to 50 parts by mass based on 100 parts by mass of the resin.
[0159] The particle size (dimension) of the metal powder or the like can be defined as the particle size (D50) at the cumulative value of 50% in the volume-based particle size distribution obtained by the laser diffraction / scattering method. The measurement by the laser diffraction / scattering method can be performed, for example, by using a MICROTRAC particle size analyzer MT3300EX (manufactured by Nikkiso Co., Ltd.).
[0160] [(E) ingredient]
[0161] The biological electrode composition of the present invention may further contain additives as component (E) as necessary. Examples of additives include moisturizing ingredients such as polyether, polyglycerol, polyglycerol ester, polyether polysilicone, polyglycerol polysilicone, and salts such as sodium chloride, potassium chloride, calcium chloride, magnesium chloride, saccharin sodium salt, acesulfame potassium, sodium carboxylate, potassium carboxylate, calcium carboxylate, sodium sulfonate, potassium sulfonate, calcium sulfonate, sodium phosphate, potassium phosphate, calcium phosphate, magnesium phosphate, and betaine for improving ion conductivity. Examples of additives include polysilicone compounds and inorganic particles having a polyglycerol structure as described later.
[0162] (Adhesiveness Imparting Agent)
[0163] In order to impart adhesion to the organism, an adhesion imparting agent may be added to the bioelectrode composition. Such adhesion imparting agents include, for example, silicone resin, non-crosslinked siloxane, non-crosslinked poly (meth) acrylate, non-crosslinked polyether, and the like.
[0164] (Crosslinking agent)
[0165] An epoxy-based crosslinking agent may also be added to the bioelectrode composition. The crosslinking agent in this case is a compound having a plurality of epoxy groups or oxetane groups in one molecule. The amount added is 1 to 30 parts by mass relative to 100 parts by mass of the resin.
[0166] (Cross-linking catalyst)
[0167] A catalyst for cross-linking epoxy groups and oxetane groups may also be added to the bioelectrode composition. In this case, the catalyst described in paragraphs 0027 to 0029 of JP-A-2019-503406 may be used. The amount added is 0.01 to 10 parts by mass relative to 100 parts by mass of the resin.
[0168] (Ionic Additives)
[0169] Ionic additives for improving ionic conductivity may be added to the biological electrode composition. Considering biological compatibility, sodium chloride, potassium chloride, calcium chloride, saccharin sodium salt, acesulfame potassium, salts of JP-A-2018-44147, JP-A-2018-59050, JP-A-2018-59052, and JP-A-2018-130534 may be cited.
[0170] (Polysilicone compound having a polyglycerol structure)
[0171] In the biological electrode composition of the present invention, a polysilicone compound having a polyglycerol structure may be added to improve the moisture retention of the membrane and the sensitivity and ion conductivity of ions released from the skin. The amount of the polysilicone compound having a polyglycerol structure is not particularly limited, but is preferably 0.01 to 100 parts by mass, and more preferably 0.5 to 60 parts by mass, relative to 100 parts by mass of the total of the components (A) and (B). The polysilicone compound having a polyglycerol structure may be used alone or in combination of two or more.
[0172] The polysilicone compound having a polyglycerol structure is preferably represented by the following general formula (4) and (5).
[0173] [Chemistry 5]
[0174]
[0175] In formula (4) and (5), R 1’ Each of them is independent of the other and may be the same or different, and is a hydrogen atom or a linear or branched alkyl group having 1 to 50 carbon atoms, or a phenyl group, and may contain an ether group, or may be a polysiloxane chain represented by the general formula (6). 2’ is a group having a polyglyceryl structure represented by formula (4)-1 or formula (4)-2, R 3’ Each is independent and may be the same or different from each other, and is the aforementioned R1’ The group or the aforementioned R 2’ Group, R 4’ Each is independent and may be the same or different from each other, and is the aforementioned R 1’ Group, the aforementioned R 2’ A group or an oxygen atom. 4’ When it is an oxygen atom, R 4’ The groups may also be bonded to form an ether group and form a ring with the silicon atom. a' may be the same or different and is 0 to 100, b' is 0 to 100, and a'+b' is 0 to 200. However, when b' is 0, R 3 ' is the aforementioned R 2’ In formula (4)-1, (4)-2 and (5), R 5’ is an alkylene group having 2 to 10 carbon atoms or an aralkylene group having 7 to 10 carbon atoms, R 6’ and R 7’ is an alkylene group having 2 to 6 carbon atoms, R 7’ It may also be an ether bond, c' is 0 to 20, and d' is 1 to 20. 8’ It is a hydrogen atom, a linear or branched alkyl group having 1 to 50 carbon atoms which may contain an ether group, or a phenyl group.
[0176] Examples of such polysilicone compounds having a polyglycerol structure include the following.
[0177] [Chemistry 6]
[0178]
[0179] [Chemistry 7]
[0180]
[0181] [Chemistry 8]
[0182]
[0183] [Chemistry 9]
[0184]
[0185] [Chemistry 10]
[0186]
[0187] [Chemistry 11]
[0188]
[0189] [Chemistry 12]
[0190]
[0191] [Chemistry 13]
[0192]
[0193] [Chemistry 14]
[0194]
[0195] [Chemistry 15]
[0196]
[0197] In the formula, a', b', c' and d' are as described above.
[0198] When such a polysilicone compound having a polyglycerol structure is contained, it is possible to exhibit better moisture retention, and as a result, it is possible to obtain a bioelectrode composition capable of forming a biocontact layer that exhibits better sensitivity to ions released from the skin.
[0199] (Other additives)
[0200] Inorganic particles such as silicon dioxide particles, aluminum oxide particles, titanium oxide particles, and zirconium oxide particles can also be mixed in the biological electrode composition. The surface of silicon dioxide particles, aluminum oxide particles, titanium oxide particles, and zirconium oxide particles is hydrophilic, and has good compatibility with hydrophilic ionic polymers and polyglycerol polysilicone, which can make the dispersibility of ionic polymers in hydrophobic polysilicone adhesives and polyglycerol polysilicone in polysilicone adhesives better. Silica particles, aluminum oxide particles, titanium oxide particles, and zirconium oxide particles can be used ideally in dry and wet methods. The shapes of silicon dioxide particles, aluminum oxide particles, titanium oxide particles, and zirconium oxide particles can be spherical, elliptical, indefinite, hollow, and porous. In addition, the surface of particles such as silicon dioxide can also be surface-modified using silane coupling agents, polysilicone, etc.
[0201] <Method for producing biological electrode composition>
[0202] The method for manufacturing the biological electrode composition of the present invention is not particularly limited. For example, (A) an ionic polymer material, (B) an addition reaction-hardening polysiloxane having at least a hydrogen silicon group, and (C) a platinum group catalyst can be stored in separate containers and mixed to form the biological electrode composition when manufacturing the biological electrode.
[0203] As described above, it is preferred that the ionic polymer material and the organohydrogensiloxane having a hydrosilyl group be stored in separate containers, mixed with a platinum-based catalyst when curing by hydrosilylation reaction, applied to form a film, and baked to perform curing by hydrosilylation reaction. Even if the solvent containing the ionic polymer compound is dehydrated to remove water, it still contains trace amounts of water because silanol is gradually generated during long-term storage.
[0204] When the component (D) is contained, the component (D) may be mixed with the component (A) or the component (B) before or simultaneously with the component (C).
[0205] Thereby, the influence due to the water|moisture content from (D)component can be reduced.
[0206] (Dehydration treatment)
[0207] As mentioned above, the one that easily contains water is not the polysiloxane with hydrogen silyl groups of component (B), but the solution of the ionic polymer material containing component (A) containing a polar solvent. When the water contained in the solution (A) is mixed with the solution (B), it will cause the deactivation reaction of the hydrogen silyl groups mentioned above. Therefore, the solution of the ionic polymer compound containing component (A) is dehydrated as needed. The dehydration treatment can be carried out according to the usual method, for example, by azeotropic dehydration to increase the concentration of the solution containing the ionic polymer compound, or by using a dehydrating agent such as a molecular sieve.
[0208] As described above, the bioelectrode composition of the present invention can form a bioelectrode contact layer for a bioelectrode that can transmit electrical signals from the skin to a device with good efficiency (i.e., excellent conductivity), does not cause allergies even if installed on the skin for a long period of time (i.e., excellent biocompatibility), is lightweight, can be manufactured at low cost, and does not significantly reduce conductivity even if it is wetted by water or dried. In addition, by adding conductive powder (carbon powder, metal powder, etc.), the conductivity can be made better, and by combining with a resin having adhesiveness and elasticity, a bioelectrode with particularly high adhesiveness and high elasticity can be manufactured. In addition, additives can be used to make the elasticity and adhesion to the skin better, and the elasticity and adhesion can be adjusted by appropriately adjusting the composition of the resin and the thickness of the biocontact layer.
[0209] <Biological Electrode>
[0210] Furthermore, the present invention provides a bioelectrode comprising a conductive substrate and a biocontact layer formed on the conductive substrate, wherein the biocontact layer is a cured product of the bioelectrode composition of the present invention.
[0211] The biological electrode of the present invention will be described in detail below with reference to the drawings, but the present invention is not limited to these drawings.
[0212] Figure 1 A schematic cross-sectional view showing an example of the biological electrode of the present invention. Figure 1The bioelectrode 1 comprises: a conductive substrate 2, and a biocontact layer 3 formed on the conductive substrate 2. The biocontact layer 3 is formed of a cured product of the bioelectrode composition of the present invention. The biocontact layer 3 may include a resin 6, an ionic polymer 5, and a conductivity enhancer 4. Figure 1 , 2 , the description is made with respect to the case where the biological contact layer 3 is a layer in which the conductivity enhancer 4 and the ionic polymer 5 are dispersed in the resin 6, but the biological electrode of the present invention is not limited to this aspect.
[0213] Use such Figure 1 When the biological electrode 1 is Figure 2 , the bio-contact layer 3 (i.e., the layer obtained by dispersing the conductivity enhancer 4 and the ionic polymer 5 in the resin 6) is brought into contact with the bio-body 7, and the electrical signal is taken out from the bio-body 7 by using the conductivity enhancer 4 and the ionic polymer 5, and the electrical signal is conducted to the sensor device or the like (not shown) via the conductive substrate 2. As described above, in the bio-electrode of the present invention, the above-mentioned ionic polymer and the conductivity enhancer can take into account both the conductivity and the bio-compatibility, and also have the adhesiveness, so the contact area with the skin is constant, and the electrical signal from the skin can be stably obtained with high sensitivity.
[0214] The constituent materials of the biological electrode of the present invention are described in more detail below.
[0215] [Conductive substrate]
[0216] The biological electrode of the present invention has a conductive substrate. This conductive substrate is usually electrically connected to a sensor device or the like, and transmits an electrical signal extracted from the biological body through the biological contact layer to the sensor device or the like.
[0217] The conductive substrate is not particularly limited as long as it has conductivity, and preferably contains one or more selected from gold, silver, silver chloride, platinum, aluminum, magnesium, tin, tungsten, iron, copper, nickel, stainless steel, chromium, titanium, carbon and a conductive polymer.
[0218] The conductive substrate is not particularly limited, and may be a hard conductive substrate, a flexible conductive film, a cloth coated with a conductive paste, or a cloth mixed with a conductive polymer. The conductive substrate may be flat, may have irregularities, or may be a mesh woven with metal wires, and may be appropriately selected according to the purpose of the biological electrode.
[0219] [Biological contact layer]
[0220] The bioelectrode of the present invention has a biocontact layer formed on a conductive substrate. This biocontact layer is the part that actually contacts the bioelectrode when the bioelectrode is used, and has conductivity and adhesiveness. The biocontact layer is a hardened product of the bioelectrode composition of the present invention, that is, the above-mentioned component (A), component (B), and component (C) are mixed and hardened into an adhesive resin layer after coating. Components (A) and (B) may contain polysiloxane and MQ resin having alkenyl groups, and may also contain components (D) and (E) as needed.
[0221] Furthermore, the adhesion of the biological contact layer is preferably in the range of 0.5 N / 25 mm or more and 20 N / 25 mm or less. The method for measuring the adhesion is generally the method shown in JIS Z 0237. The substrate can be a metal substrate such as SUS (stainless steel) or a PET (polyethylene terephthalate) substrate, but human skin can also be used for measurement. The surface energy of human skin is lower than that of metal and various plastics, and is close to the low energy of Teflon (registered trademark), which is not easy to adhere.
[0222] The thickness of the biocontact layer of the bioelectrode is preferably 1 μm to 5 mm, and more preferably 2 μm to 3 mm. The thinner the biocontact layer, the lower the adhesion, but the flexibility is improved, and the weight is reduced, and the compatibility with the skin is improved. The thickness of the biocontact layer can be selected by comprehensively considering the adhesion and the touch to the skin.
[0223] In addition, the biological electrode of the present invention, like the biological electrode of the past (for example, the biological electrode described in Japanese Patent Gazette No. 2004-033468), can also be provided with an adhesive film on the biological contact layer in order to prevent the biological electrode from peeling off from the biological body during use. When the adhesive film is provided, an adhesive film material such as acrylic, carbamate, or silicone can be used to form the adhesive film. In particular, silicone is ideal because it has high oxygen permeability, so the skin can still breathe when attached, and it also has high water repellency, so the adhesion is less reduced due to sweat, and it has low irritation to the skin. In addition, the biological electrode of the present invention, as described above, can be prevented from peeling off from the biological body by adding an adhesiveness imparting agent to the biological electrode composition, or by using a resin with good adhesion to the biological body, so the above-mentioned adhesive film is not necessarily required.
[0224] When the biological electrode of the present invention is used as a wearable device, there are no particular limitations on the wiring and other components between the biological electrode and the sensor device, and for example, those described in Japanese Patent Application Laid-Open No. 2004-033468 may be used.
[0225] As described above, if it is a biological electrode of the present invention, the biological contact layer is formed by the hardened material of the biological electrode composition of the present invention, so the electrical signal from the skin can be transmitted to the device with good efficiency (that is, excellent conductivity), even if it is installed on the skin for a long time, there is no risk of allergies (that is, excellent biocompatibility), it is lightweight, can be manufactured at low cost, and the conductivity does not drop significantly even if it is wetted by water or dried. In addition, by adding conductive powder, the conductivity can be made better, and by combining with a resin with adhesion and elasticity, a biological electrode with particularly high adhesion and high elasticity can be manufactured. In addition, additives can be used to make the elasticity and adhesion to the skin better, and the elasticity and adhesion can be adjusted by appropriately adjusting the composition of the resin and the thickness of the biological contact layer. Therefore, such a biological electrode of the present invention is particularly suitable as a biological electrode used in a medical wearable device.
[0226] <Method for producing biological electrode>
[0227] Furthermore, the present invention provides a method for manufacturing a biological electrode, which is a method for manufacturing a biological electrode having a conductive substrate and a biological contact layer formed on the conductive substrate, by coating the above-mentioned biological electrode composition of the present invention on the aforementioned conductive substrate and hardening it to form the aforementioned biological contact layer.
[0228] Furthermore, the conductive substrate and the like used in the method for producing the biological electrode of the present invention may be the same as those described above.
[0229] The method of coating the bioelectrode composition on the conductive substrate is not particularly limited, and methods such as dip coating, spray coating, spin coating, roller coating, flow coating, doctor blade coating, screen printing, flexographic printing, gravure printing, inkjet printing, etc. are suitable.
[0230] The method for curing the resin is not particularly limited, and can be appropriately selected depending on the components (A) and (B) used in the biological electrode composition. For example, it is better to activate the platinum-based catalyst by using either heat or light or both of them, and to cure it by performing an addition reaction between the hydrogen silyl group and the polysiloxane bonded to the olefinic group.
[0231] The temperature during heating is not particularly limited and can be appropriately selected depending on the components (A) and (B) used in the bioelectrode composition, and is preferably about 50 to 250°C, for example.
[0232] When heating and irradiation are combined, heating and irradiation may be performed simultaneously, heating may be performed after irradiation, or irradiation may be performed after heating. In addition, air drying may be performed before heating after coating in order to evaporate the solvent.
[0233] When the water content of components (A) and (B) is high or a solvent containing a hydroxyl group, a carboxyl group, a nitrogen atom, or a thiol group is mixed in component (A), the deactivation reaction of the hydrogen silyl group proceeds immediately after the components (A) and (B) are mixed. In this case, after the components (A) are mixed with components (B) and (C) and left to stand, a bioelectrode is printed, hardened, and attached to the skin, and a biosignal is obtained, and then peeled off, residue will appear on the skin. The reason is that the deactivation of the hydrogen silyl group causes the cohesion destruction caused by the decrease in the crosslinking density in the bioelectrode membrane. Even if the components are printed quickly after mixing, the same phenomenon will occur if the time until hardening such as baking is long.
[0234] If water is dripped on the surface of the hardened film, or water vapor or mist is blown, the compatibility with the skin will be improved, and biological signals can be quickly obtained. In order to make the water droplets of water vapor or mist smaller, water mixed with alcohol can also be used. It is also possible to wet the surface of the film by contacting with water-containing absorbent cotton or cloth.
[0235] The water that wets the surface of the hardened film may also contain salt. The water-soluble salt mixed with water is selected from sodium salt, potassium salt, calcium salt, magnesium salt, and betaine.
[0236] The water-soluble salt may be specifically selected from sodium chloride, potassium chloride, calcium chloride, magnesium chloride, saccharin sodium salt, acesulfame potassium, sodium carboxylate, potassium carboxylate, calcium carboxylate, sodium sulfonate, potassium sulfonate, calcium sulfonate, sodium phosphate, potassium phosphate, calcium phosphate, magnesium phosphate, and betaine. The water-soluble salt does not include the polymer compound (A).
[0237] More specifically, in addition to the above, there can be mentioned sodium acetate, sodium propionate, sodium trimethylacetate, sodium glycolate, sodium butyrate, sodium valerate, sodium caproate, sodium heptanoate, sodium octanoate, sodium nonanoate, sodium decanoate, sodium undecylate, sodium laurate, sodium tridecylate, sodium myristate, sodium pentadecylate, sodium palmitate, sodium heptadecanoate, sodium stearate, sodium benzoate, disodium adipate, disodium maleate, disodium phthalate, sodium 2-hydroxybutyrate, sodium 3-hydroxybutyrate, sodium 2-oxobutyrate, sodium gluconate, sodium methanesulfonate, Sodium 1-nonanesulfonate, sodium 1-decanesulfonate, sodium 1-dodecanesulfonate, sodium 1-undecanesulfonate, sodium coconut fat isethionate, sodium lauroyl methyl alanine, sodium coconut fat methyl taurate, sodium coconut fat glutamate, sodium coconut fat, sodium lauroyl methyl taurate, lauramide propyl, potassium isobutyrate, potassium propionate, potassium trimethylacetate, potassium glycolate, potassium gluconate, potassium methanesulfonate, calcium stearate, calcium glycolate, calcium gluconate, calcium 3-methyl-2-oxobutyrate, calcium methanesulfonate. Betaine is a general term for intramolecular salts, specifically, a compound in which three methyl groups are added to the amino group of an amino acid, more specifically, trimethylglycine, carnitine, and proline betaine.
[0238] The water-soluble salt may further contain a monohydric alcohol or a polyhydric alcohol having 1 to 4 carbon atoms. The alcohol is preferably selected from ethanol, isopropanol, ethylene glycol, diethylene glycol, triethylene glycol, glycerol, polyethylene glycol, polypropylene glycol, polyglycerol, diglycerol, or a polysilicone compound having a polyglycerol structure. The polysilicone compound having a polyglycerol structure is more preferably represented by the general formula (4) and (5).
[0239] By using a pretreatment method using an aqueous solution containing a water-soluble salt, the biological electrode membrane can be coated on the hardened biological electrode membrane by spraying, water drop dispensing, etc. The coating can also be performed in a high temperature and high humidity state like a sauna. After coating, in order to prevent drying, a protective film can be further laminated on the permeable layer for covering. The protective film needs to be peeled off just before being attached to the skin, so a Teflon (registered trademark) film coated with a peeling agent or peelable can be used. For long-term storage, the dry electrode covered with a peeling film is preferably sealed in a bag covered with aluminum or the like. In order to prevent drying in the aluminum-covered bag, it is better to seal water in it in advance.
[0240] Before attaching the biological electrode of the present invention to the skin, the skin side may be wetted with water, alcohol, etc., or the skin may be wiped with a cloth or absorbent cotton containing water, alcohol, etc. The water or alcohol may also contain the aforementioned salt.
[0241] As described above, the method for manufacturing the biological electrode of the present invention can easily manufacture the biological electrode of the present invention at low cost, which has excellent conductivity and biocompatibility, is lightweight, and does not significantly reduce conductivity even when wetted by water or dried.
[0242] [Example]
[0243] The present invention will be specifically described below using Examples and Comparative Examples, but the present invention is not limited thereto. "Me" represents a methyl group, and "Vi" represents a vinyl group.
[0244] Synthesis Example 1
[0245] The ionic polymer 1 solution mixed as an ionic material (conductive material) in the biological electrode composition is synthesized in the following manner. A 20% by mass PGMEA solution of each monomer is placed in a reaction container and mixed, and the reaction container is cooled to -70°C in a nitrogen environment, and degassing and nitrogen blowing under reduced pressure are repeated 3 times. After the temperature is raised to room temperature, 0.01 mol of azobisisobutyronitrile (AIBN) as a polymerization initiator is added to 1 mol of the total monomer, and the temperature is raised to 60°C, and the mixture is reacted for 15 hours. PGMEA is evaporated using an evaporator to concentrate the polymer to 30% by mass, and water is evaporated at the same time. Based on the composition of the obtained polymer, a portion of the polymer solution is dried and then used 1The molecular weight (Mw) and the degree of dispersion (Mw / Mn) of the obtained polymer were confirmed by gel permeation chromatography (GPC) using tetrahydrofuran (THF) as a solvent.
[0246] 30 mass% PGMEA solution of ionic polymer 1
[0247] Mw=38,100
[0248] Mw / Mn=1.91
[0249] [Chemistry 16]
[0250]
[0251] The number of replicates in the formula represents the average value.
[0252] Synthesis Example 2
[0253] In the same manner as in Synthesis Example 1, 2-heptanone was used as the polymerization solvent to prepare an ionic polymer 2 solution.
[0254] 30 mass% ionic polymer 2 solution in 2-heptanone
[0255] Mw=32,100
[0256] Mw / Mn=1.99
[0257] [Chemistry 17]
[0258]
[0259] The number of replicates in the formula represents the average value.
[0260] Synthesis Example 3
[0261] In the same manner as in Synthesis Example 1, an ionic polymer 3 solution was prepared using 2-ethoxycarbonylcyclopentanone as a polymerization solvent.
[0262] 30 mass% solution of ionic polymer 3 in 2-ethoxycarbonylcyclopentanone
[0263] Mw=33,300
[0264] Mw / Mn=1.83
[0265] [Chemistry 18]
[0266]
[0267] The number of replicates in the formula represents the average value.
[0268] Synthesis Example 4
[0269] In the same manner as in Synthesis Example 1, cyclohexanone was used as a polymerization solvent to prepare an ionic polymer 4 solution.
[0270] 30 mass% cyclohexanone solution of ionic polymer 4
[0271] Mw=80,100
[0272] Mw / Mn=2.15
[0273] [Chemistry 19]
[0274]
[0275] Synthesis Example 5
[0276] In the same manner as in Synthesis Example 1, cyclopentanone was used as a polymerization solvent to prepare an ionic polymer 5 solution.
[0277] 30 mass% cyclopentanone solution of ionic polymer 5
[0278] Mw=44,400
[0279] Mw / Mn=1.94
[0280] [Chemistry 20]
[0281]
[0282] The number of replicates in the formula represents the average value.
[0283] Synthesis Example 6
[0284] In the same manner as in Synthesis Example 1, a solution of ionic polymer 6 was prepared using 2-propylcyclohexanone as a polymerization solvent.
[0285] 30 mass% solution of ionic polymer 6 in 2-propylcyclohexanone
[0286] Mw=41,100
[0287] Mw / Mn=1.86
[0288] [Chemistry 21]
[0289]
[0290] The number of replicates in the formula represents the average value.
[0291] Synthesis Example 7
[0292] In the same manner as in Synthesis Example 1, a solution of ionic polymer 7 was prepared using 2-acetylcyclohexanone as a polymerization solvent.
[0293] 30 mass% solution of ionic polymer 7 in 2-acetylcyclohexanone
[0294] Mw=43,600
[0295] Mw / Mn=1.93
[0296] [Chemistry 22]
[0297]
[0298] Synthesis Example 8
[0299] In the same manner as in Synthesis Example 1, a solution of ionic polymer 8 was prepared using 2-pentyl-2-cyclopenten-1-one as a polymerization solvent.
[0300] 30 mass% solution of ionic polymer 8 in 2-pentyl-2-cyclopenten-1-one
[0301] Mw=35,700
[0302] Mw / Mn=2.06
[0303] [Chemistry 23]
[0304]
[0305] The number of replicates in the formula represents the average value.
[0306] Synthesis Example 9
[0307] In the same manner as in Synthesis Example 1, a solution of ionic polymer 9 was prepared using 2-heptylcyclopentanone as a polymerization solvent.
[0308] 30 mass% solution of ionic polymer 9 in 2-heptylcyclopentanone
[0309] Mw=55,100
[0310] Mw / Mn=2.02
[0311] [Chemistry 24]
[0312]
[0313] The number of replicates in the formula represents the average value.
[0314] Synthesis Example 10
[0315] In the same manner as in Synthesis Example 1, 3,3,5-trimethylcyclohexanone was used as a polymerization solvent to prepare an ionic polymer 10 solution.
[0316] 30 mass% solution of ionic polymer 10 in 3,3,5-trimethylcyclohexanone
[0317] Mw=87,500
[0318] Mw / Mn=2.01
[0319] [Chemistry 25]
[0320]
[0321] The number of replicates in the formula represents the average value.
[0322] Synthesis Example 11
[0323] In the same manner as in Synthesis Example 1, a solution of an ionic polymer 11 was prepared using 2-methoxycarbonylcyclopentanone as a polymerization solvent.
[0324] 30 mass% solution of ionic polymer 11 in 2-methoxycarbonylcyclopentanone
[0325] Mw=41,600
[0326] Mw / Mn=1.91
[0327] [Chemistry 26]
[0328]
[0329] The number of replicates in the formula represents the average value.
[0330] Synthesis Example 12
[0331] In the same manner as in Synthesis Example 1, a solution of an ionic polymer 12 was prepared using γ-valerolactone as a polymerization solvent.
[0332] 30 mass% γ-valerolactone solution of ionic polymer 12
[0333] Mw36,100
[0334] Mw / Mn=1.55
[0335] [Chemistry 27]
[0336]
[0337] The number of replicates in the formula represents the average value.
[0338] Synthesis Example 13
[0339] In the same manner as in Synthesis Example 1, an ionic polymer 13 solution was prepared using ε-caprolactone as a polymerization solvent.
[0340] 30 mass% ε-caprolactone solution of ionic polymer 13
[0341] Mw=38,300
[0342] Mw / Mn=2.01
[0343] [Chemistry 28]
[0344]
[0345] The number of replicates in the formula represents the average value.
[0346] Synthesis Example 14
[0347] In the same manner as in Synthesis Example 1, cycloheptanone was used as a polymerization solvent to prepare an ionic polymer 14 solution.
[0348] 30 mass% ionic polymer 14 solution in cycloheptanone
[0349] Mw=33,500
[0350] Mw / Mn=1.97
[0351] [Chemistry 29]
[0352]
[0353] The number of replicates in the formula represents the average value.
[0354] Synthesis Example 15
[0355] In the same manner as in Synthesis Example 1, a solution of an ionic polymer 15 was prepared using 3-methylcyclohexanone as a polymerization solvent.
[0356] 30 mass% solution of ionic polymer 15 in 3-methylcyclohexanone
[0357] Mw=34,900
[0358] Mw / Mn=1.91
[0359] [Chemistry 30]
[0360]
[0361] The number of replicates in the formula represents the average value.
[0362] Synthesis Example 16
[0363] In the same manner as in Synthesis Example 1, a solution of ionic polymer 16 was prepared using diethylene glycol diethyl ether as a polymerization solvent.
[0364] 30 mass% diethylene glycol diethyl ether solution of ionic polymer 16
[0365] Mw=43,100
[0366] Mw / Mn=1.74
[0367] [Chemistry 31]
[0368]
[0369] The number of replicates in the formula represents the average value.
[0370] Synthesis Example 17
[0371] In the same manner as in Synthesis Example 1, a solution of ionic polymer 17 was prepared using diethylene glycol methyl butyl ether as a polymerization solvent.
[0372] 30 mass% diethylene glycol methyl butyl ether solution of ionic polymer 17
[0373] Mw=42,000
[0374] Mw / Mn=1.77
[0375] [Chemistry 32]
[0376]
[0377] The number of replicates in the formula represents the average value.
[0378] Synthesis Example 18
[0379] In the same manner as in Synthesis Example 1, a solution of ionic polymer 18 was prepared using diethylene glycol dibutyl ether as a polymerization solvent.
[0380] 30 mass% diethylene glycol dibutyl ether solution of ionic polymer 18
[0381] Mw=41,000
[0382] Mw / Mn=1.69
[0383] [Chemistry 33]
[0384]
[0385] The number of replicates in the formula represents the average value.
[0386] Synthesis Example 19
[0387] In the same manner as in Synthesis Example 1, a solution of ionic polymer 19 was prepared using diethylene glycol butyl ether acetate as a polymerization solvent.
[0388] 30 mass% diethylene glycol butyl ether acetate solution of ionic polymer 19
[0389] Mw=37,000
[0390] Mw / Mn=1.61
[0391] [Chemistry 34]
[0392]
[0393] The number of replicates in the formula represents the average value.
[0394] Synthesis Example 20
[0395] According to the same method as Synthesis Example 19, the ionic monomer was changed and diethylene glycol butyl ether acetate was used as the polymerization solvent to prepare an ionic polymer 20 solution.
[0396] 30 mass% ionic polymer 20 in diethylene glycol butyl ether acetate solution
[0397] Mw=39,000
[0398] Mw / Mn=1.64
[0399] [Chemistry 35]
[0400]
[0401] The number of replicates in the formula represents the average value.
[0402] Synthesis Example 21
[0403] According to the same method as Synthesis Example 19, the ionic monomer was changed and diethylene glycol butyl ether acetate was used as the polymerization solvent to prepare an ionic polymer 21 solution.
[0404] 30 mass% diethylene glycol butyl ether acetate solution of ionic polymer 21
[0405] Mw=44,000
[0406] Mw / Mn=1.68
[0407] [Chemistry 36]
[0408]
[0409] The number of replicates in the formula represents the average value.
[0410] Synthesis Example 22
[0411] According to the same method as Synthesis Example 19, the ionic monomer was changed and diethylene glycol butyl ether acetate was used as the polymerization solvent to prepare an ionic polymer 22 solution.
[0412] 30 mass% ionic polymer 22 in diethylene glycol butyl ether acetate solution
[0413] Mw=48,000
[0414] Mw / Mn=1.81
[0415] [Chemistry 37]
[0416]
[0417] The number of replicates in the formula represents the average value.
[0418] Comparative Synthesis Example 1
[0419] In the same manner as in Synthesis Example 1, polymerization was carried out at a concentration of 30 mass % using cyclopentanone as a polymerization solvent without performing a dehydration treatment, thereby preparing a comparative ionic polymer 1 solution.
[0420] 30 mass% cyclopentanone solution of comparative ionic polymer 1
[0421] Mw=44,400
[0422] Mw / Mn=1.98
[0423] [Chemistry 38]
[0424]
[0425] The number of replicates in the formula represents the average value.
[0426] Comparative Synthesis Example 2
[0427] In the same manner as in Synthesis Example 1, polymerization was carried out at a concentration of 30 mass % using PGEE as a polymerization solvent without using a dehydration treatment to prepare a comparative ionic polymer 2 solution.
[0428] 30 mass% PGEE solution of comparative ionic polymer 2
[0429] Mw=46,600
[0430] Mw / Mn=1.95
[0431] [Chemistry 39]
[0432]
[0433] The number of replicates in the formula represents the average value.
[0434] Comparative Synthesis Example 3
[0435] In the same manner as in Synthesis Example 1, polymerization was carried out using diacetone alcohol as a polymerization solvent to prepare a comparative ionic polymer 3 solution.
[0436] 30 mass% diacetone alcohol solution of comparative ionic polymer 3
[0437] Mw=36,600
[0438] Mw / Mn=1.92
[0439] [Chemistry 40]
[0440]
[0441] The number of replicates in the formula represents the average value.
[0442] Polyglycerol polysiloxane compounds 1 to 5 (additives) are shown below. The synthesis method of these compounds is described in Japanese Patent Application Laid-Open No. 2019-99469, and they are synthesized by hydrosilylation reaction of polysiloxane compounds having SiH groups and polyglycerol compounds having double bonds in the presence of a platinum catalyst.
[0443] [Chemistry 41]
[0444]
[0445] Siloxane compounds 1 to 4 blended as polysiloxane-based resins in the bioelectrode composition are shown below.
[0446] (Siloxane compound 1)
[0447] As the siloxane compound 1, a vinyl-containing polydimethylsiloxane having a viscosity of 27,000 mPa·s in a 30% toluene solution, an alkenyl content of 0.007 mol / 100 g, and a molecular chain terminal blocked with a SiMe2Vi group was used.
[0448] (Siloxane compound 2)
[0449] Me3SiO 0.5 Polysiloxane (Me3SiO 0.5 As the siloxane compound 2, a 60% ISOPAR G solution was prepared.
[0450] (Siloxane compound 3)
[0451] 40 parts by weight of vinyl-containing polydimethylsiloxane having a viscosity of 42,000 mPa·s in a 30% toluene solution, an olefin content of 0.007 mol / 100 g, and OH-terminated molecular chain ends, and 40 parts by weight of Me3SiO 0.5 MQ resin composed of polysiloxane (Me3SiO 0.5Siloxane compound 3 was prepared by heating a solution composed of 100 parts by mass of a 60% ISOPAR G solution having an SiO2 unit / SiO2 unit=0.8) and 26.7 parts by mass of ISOPAR G under reflux for 4 hours and then cooling to bond polydimethylsiloxane to the MQ resin.
[0452] (Siloxane compound 4)
[0453] As the polysilicone having a hydrosilyl group, KF-99 manufactured by Shin-Etsu Chemical Co., Ltd. was used.
[0454] As the silicone-based resin, KF-353 manufactured by Shin-Etsu Chemical Co., Ltd., which is a side-chain polyether-modified polyether-type silicone oil, was used.
[0455] The organic solvents blended in the bioelectrode composition are as follows.
[0456] PGMEA: Propylene glycol-1-monomethyl ether-2-acetate
[0457] PGEE: 1-ethoxy-2-propanol
[0458] DAA: diacetone alcohol
[0459] ISOPAR G: Isoparaffin solvent standard petroleum
[0460] ISOPAR M: Isoparaffin solvent standard petroleum
[0461] The platinum catalyst, conductivity enhancer (metal powder, carbon black, carbon nanotubes, lithium titanate, graphite, ion-treated graphite, ion-treated carbon black, metal chloride), and additive (addition reaction control agent) added as additives to the biological electrode composition are shown below.
[0462] Platinum catalyst: CAT-PL-56 manufactured by Shin-Etsu Chemical Co., Ltd. (platinum content: 2 mass%)
[0463] Metal powder Silver powder: Made by Sigma-Aldrich, silver flake diameter 10 μm
[0464] Gold powder: Made by Sigma-Aldrich, gold powder diameter less than 10 μm
[0465] Carbon black: Denka Black Li-400 manufactured by Denka Corporation
[0466] Multilayered carbon nanotubes: manufactured by Sigma-Aldrich, with a diameter of 110-170 nm and a length of 5-9 μm
[0467] Lithium titanate powder, spinel: manufactured by Sigma-Aldrich, size less than 200nm
[0468] Graphite: Made by Sigma-Aldrich, diameter less than 20 μm
[0469] Ion-treated graphite 1: prepared according to the following Preparation Example 1.
[0470] Ion-treated carbon black 1, 2: prepared according to the following preparation examples 2, 3.
[0471] Metal chloride powder Sodium chloride powder: powder
[0472] Potassium chloride powder: powder
[0473] Addition reaction controller: 1-ethynylcyclohexanol
[0474] (Preparation Example 1)
[0475] 10 mass % of the graphite dispersed in the methanol containing 1 mass % of sodium chloride was stirred at 60° C. for 10 hours to evaporate the methanol, thereby producing ion-treated graphite 1 .
[0476] (Preparation Example 2)
[0477] 10 mass % of DENKA BLACK Li-400 dispersed in the methanol containing 1 mass % of sodium chloride was stirred at 60° C. for 10 hours, and the methanol was evaporated to prepare ion-treated carbon black 1.
[0478] (Preparation Example 3)
[0479] Ion-treated carbon black 2 is prepared by following the same method as in Preparation Example 2, replacing sodium chloride with the above-mentioned potassium chloride.
[0480] [Examples 1 to 27, Comparative Examples 1 to 3]
[0481] According to the compositions described in Tables 1 to 3, ionic polymers (ionomers), polysiloxane containing hydrogen silicon groups, polysiloxane resins, organic solvents, conductivity enhancers, and additives (polyglycerol, addition reaction control agents) were blended to prepare components (A) and (B), and component (C) was added thereto and mixed in the proportions described in Tables 4 and 5. The water contents (mass %) of components (A) (A solutions 1 to 26, comparative A solutions 1 to 3) and components (B) (B solutions 1 to 3) were measured by the Karl Fischer method. In addition, regarding the water content in the bioelectrode composition obtained by mixing components (A), (B) and (C), the blending ratio of component (C) was very small and the water from it could be ignored, so it was determined from the blending amounts (mass parts) of components (A) and (B) and the water content. The water contents in the bioelectrode compositions of Examples 1 to 27 were all 0.2% by mass or less.
[0482] [Table 1]
[0483]
[0484]
[0485] [Table 2]
[0486]
[0487] [Table 3]
[0488]
[0489] (Biological signal evaluation)
[0490] The conductive paste DOTITE FA-333 manufactured by Fujikura Chemical was applied to ST-604 of Bemis' thermoplastic urethane (TPU) film by screen printing, and then baked in an oven at 120°C for 10 minutes to print a keyhole-shaped conductive pattern with a circular diameter of 2 cm. The mixture of components A to C listed in Tables 1 to 3 (bioelectrode composition) was mixed for 1 hour, and then applied to the circular portion overlapping the conductive pattern by screen printing. After air drying at room temperature for 10 minutes, the mixture was baked in an oven at 125°C for 10 minutes to evaporate the solvent and harden it, thereby obtaining a bioelectrode ( Figure 3 ). The urethane film on which the bioelectrode has been printed was cut and a double-sided tape was attached to prepare three bioelectrodes (bioelectrode samples) with one composition solution ( Figure 4 ). Here, Figure 3 The figure shows a biological electrode 1 obtained by printing a conductive pattern 2 on a thermoplastic urethane film 20 and preparing a biological contact layer 3 which is cured. Figure 4 , showing a biological electrode sample 10 obtained by cutting out a thermoplastic urethane film 20 on which a conductive pattern 2 is printed and hardened, and attaching a double-sided tape 21 thereto.
[0491] (Measurement of the thickness of the biocontact layer)
[0492] The thickness of the biocontact layer in the bioelectrode produced above was measured using a micrometer. The results are shown in Tables 4 and 5.
[0493] (Measurement of biological signals)
[0494] The conductive wiring pattern of the biological electrode obtained by using the conductive paste is connected to the portable electrocardiograph HCG-901 manufactured by Omron Healthcare Corporation with a conductive wire, and the positive electrode of the electrocardiograph is attached to the Figure 5 The negative electrode is attached to the LA of the human body, the negative electrode is attached to the LL, and the ground electrode is attached to the RA. After 20 minutes of attachment, start measuring the electrocardiogram to confirm whether Figure 6The electrocardiogram waveform (ECG signal) consisting of P, Q, R, S, and T waves was observed, and the presence of bioelectrode film residue on the skin after the bioelectrodes were peeled off was observed. The results are shown in Tables 4 and 5.
[0495] [Table 4]
[0496]
[0497] [Table 5]
[0498]
[0499] As shown in Tables 4 and 5, Examples 1 to 27 of the present invention, in which the biological electrode composition is prepared using a solution with a water content reduced to less than 0.2%, or using an ether-based, ester-based, or ketone-based solvent containing no hydroxyl group, carboxyl group, nitrogen atom, or thiol group as component (A), to form a biological contact layer, obtain good biological signals, and no residue remains on the skin after peeling.
[0500] On the other hand, when a bioelectrode composition having a water content exceeding 0.2% or a solvent containing a hydroxyl group (DAA) was used, a biosignal was obtained, but residues appeared on the skin after peeling (Comparative Examples 1 to 3).
[0501] From the above, if a biological electrode with a biological contact layer is formed using the biological electrode composition of the present invention, then the conductivity, biological compatibility, adhesion to the conductive substrate are excellent, and the ion conductivity is high, a good biological signal can be obtained, the addition reaction will not be hindered, and the cross-linking reaction in the membrane will proceed fully, so that no residue will appear on the skin even after peeling.
[0502] The present invention is not limited to the above-mentioned embodiments. The above-mentioned embodiments are merely examples, and those having substantially the same configuration and exhibiting the same functions and effects as the technical concept described in the claims of the present invention are all within the technical scope of the present invention.
[0503] Description of Reference Numerals
[0504] 1: Biological Electrode
[0505] 2: Conductive substrate (conductive pattern)
[0506] 3: Bio-contact layer
[0507] 4: Conductivity enhancer
[0508] 5: Ionic polymer
[0509] 6: Resin
[0510] 7: Organisms
[0511] 10: Biological electrode samples
[0512] 20: Thermoplastic urethane film
[0513] 21: Double-sided tape
[0514] LA: positive electrode attachment
[0515] LL: Negative electrode attachment
[0516] RA: Grounding attachment
Claims
1. A biological electrode composition containing (A) an ionic polymer material, (B) an addition reaction-curable polysiloxane having at least a hydrosilyl group, (C) a platinum group-based catalyst, and a solvent, characterized in that: The water content in the biological electrode composition is 0.2% by mass or less, the water content in the component (A) is 0.2% by mass or less, and the solvent contains at least one of an ether-based, ester-based, and ketone-based solvent that does not contain a hydroxyl group, a carboxyl group, a nitrogen atom, or a thiol group.
2. The biological electrode composition according to claim 1, wherein: The biological electrode composition is a mixture of a solution containing the ionic polymer material as the component (A), the addition reaction-curable polysiloxane having at least a hydrosilyl group as the component (B), and a solution containing the platinum group-based catalyst as the component (C). The water content in the component (B) is 0.2% by mass or less.
3. The biological electrode composition according to claim 2, wherein: The solvent of the solution of the component (A) does not contain at least one of an ether-based, ester-based, and ketone-based solvent that does not contain a hydroxyl group, a carboxyl group, a nitrogen atom, or a thiol group, and the component (B) is a solvent-free or a solution in a hydrocarbon-based or ether-based solvent.
4. The biological electrode composition according to any one of claims 1 to 3, wherein The ionic polymer material in the component (A) is a polymer compound containing a repeating unit having a structure of a sodium salt, a potassium salt, or a silver salt of any one selected from fluorosulfonic acid, fluorosulfonylimide, and N-carbonylfluorosulfonamide.
5. The biological electrode composition according to claim 4, wherein: The structure is represented by the following general formula (1)-1 to (1)-4; In the formula, Rf1 and Rf2 are a hydrogen atom, a fluorine atom, an oxygen atom, a methyl group, or a trifluoromethyl group. When Rf1 is an oxygen atom, Rf2 is also an oxygen atom and forms a carbonyl group together with the bonded carbon atom. Rf3 and Rf4 are a hydrogen atom, a fluorine atom, or a trifluoromethyl group, and at least one of Rf1 to Rf4 is a fluorine atom or a trifluoromethyl group. Rf5, Rf6, and Rf7 are a fluorine atom, a linear alkyl group having 1 to 4 carbon atoms, or a branched alkyl group having 3 or 4 carbon atoms, and have at least one fluorine atom. m is an integer of 1 to 4; M is sodium, potassium, or silver.
6. The biological electrode composition according to claim 5, wherein: One or more repeating units selected from the sodium salt, potassium salt, or silver salt of fluorosulfonic acid represented by the general formula (1)-1 or (1)-2, the sodium salt, potassium salt, or silver salt of sulfonylimide represented by (1)-3, or the sodium salt, potassium salt, or silver salt of sulfonamide represented by (1)-4 have one or more repeating units selected from the repeating units a1 to a7 described in the following general formula (2); In the formula, R 1 , R 3 , R 5 , R 8 , R 10 , R 11 , and R 13 are each independently a hydrogen atom or a methyl group, R 2 , R 4 , R 6 , R 9 , and R 12 Each independently represents a single bond, an ester group, or any one of a linear, branched or cyclic divalent hydrocarbon group having 1 to 13 carbon atoms, 3 to 12 carbon atoms, and which may have either or both an ether group or an ester group; R 7 is a linear alkylene group having 1 to 4 carbon atoms or a branched alkylene group having 3 to 12 carbon atoms, R 7 One or two of the hydrogen atoms in the fluorine atom may also be substituted by a fluorine atom; X1, X2, X3, X4, and X6 are each independently a single bond, a phenylene group, a naphthylene group, an ether group, an ester group, or an amide group; X5 is a single bond, an ether group, or an ester group; X7 is a single bond, an arylene group having 6 to 12 carbon atoms, or -C(=O)-OX 10 -, X 10 is a linear, branched, or cyclic alkylene group having 1 to 12 carbon atoms, or a divalent aromatic hydrocarbon group having 6 to 10 carbon atoms, and X 10 It may also have ether group, carbonyl group, ester group; Y is an oxygen atom, or -NR 19 -group, R 19 is a hydrogen atom, a linear alkyl group having 1 to 4 carbon atoms, or a branched alkyl group having 3 or 4 carbon atoms, and Y and R 4 They can also bond and form rings; m is an integer of 1 to 4; a1, a2, a3, a4, a5, a6, and a7 are numbers that satisfy 0≤a1≤1.0, 0≤a2≤1.0, 0≤a3≤1.0, 0≤a4≤1.0, 0≤a5≤1.0, 0≤a6≤1.0, 0≤a7≤1.0, and 0<a1+a2+a3+a4+a5+a6+a7≤1.0; M, Rf5, Rf6, and Rf7 are as described above.
7. The biological electrode composition according to any one of claims 1 to 3, wherein The component (B) contains an organopolysiloxane having a hydrosilyl group.
8. The biological electrode composition according to any one of claims 1 to 3, wherein The component (B) contains an organopolysiloxane having a hydrosilyl group and contains a diorganopolysiloxane having an alkenyl group.
9. The biological electrode composition according to any one of claims 1 to 3, wherein The component (B) further contains R x SiO (4-x) / 2 The polysilicone resin has SiO2 units, R is a substituted or unsubstituted monovalent hydrocarbon group having 1 to 10 carbon atoms, and x is in the range of 2.5 to 3.
5.
10. The biological electrode composition according to any one of claims 1 to 3, wherein The component (A) contains an ionic polymer material and contains a diorganosiloxane having an alkenyl group.
11. The biological electrode composition according to claim 10, wherein: The component (A) further contains R x SiO (4-x) / 2 The polysilicone resin has SiO2 units, R is a substituted or unsubstituted monovalent hydrocarbon group having 1 to 10 carbon atoms, and x is in the range of 2.5 to 3.
5.
12. The biological electrode composition according to any one of claims 1 to 3, wherein: The component (A) or the component (B) further contains one or more selected from carbon powder, metal powder, silicon powder, lithium titanate powder and metal chloride powder as the component (D).
13. The biological electrode composition according to claim 12, wherein: The carbon powder is any one of carbon black, graphite and carbon nanotube or a combination thereof.
14. The biological electrode composition according to claim 13, wherein: The toner also contains ionic components.
15. The biological electrode composition according to claim 12, wherein: The metal powder is selected from the group consisting of gold, silver, platinum, copper, tin, titanium, nickel, aluminum, tungsten, molybdenum, ruthenium, chromium and indium.
16. The biological electrode composition according to claim 15, wherein: The metal powder is silver powder.
17. A method for producing a biological electrode composition, the method for producing a biological electrode composition according to any one of claims 1 to 16, characterized in that: The (A) ionic polymer material, the (B) addition reaction-curable polysiloxane having at least a hydrosilyl group, and the (C) platinum-group catalyst are stored in separate containers and mixed to form a bioelectrode composition when the bioelectrode is manufactured.
18. A method for producing a biological electrode composition, the method for producing a biological electrode composition according to claim 12, characterized in that: The component (D) is mixed with the component (A) or the component (B) before or simultaneously with the component (C).
19. A biological electrode comprising a conductive substrate and a biological contact layer formed on the conductive substrate, characterized in that: The living body contact layer is a hardened material of the living body electrode composition according to any one of claims 1 to 16.
20. The biological electrode according to claim 19, wherein: The conductive substrate contains one or more selected from the group consisting of gold, silver, silver chloride, platinum, aluminum, magnesium, tin, tungsten, iron, copper, nickel, stainless steel, chromium, titanium, carbon, and a conductive polymer.
21. A method for manufacturing a bioelectrode, comprising a conductive substrate and a biocontact layer formed on the conductive substrate, wherein: exist The bio-electrode composition according to any one of claims 1 to 16 is coated on the conductive substrate and cured to form the bio-contact layer.
22. The method for manufacturing a biological electrode according to claim 21, wherein: The conductive substrate may contain one or more selected from the group consisting of gold, silver, silver chloride, platinum, aluminum, magnesium, tin, tungsten, iron, copper, nickel, stainless steel, chromium, titanium, carbon, and a conductive polymer.
